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ABSTRACT OF DISSERTATION 
 
 
 
 
FUS is an RNA binding protein implicated in the motor neuron disease—
amyotrophic lateral sclerosis (ALS, also called Lou Gehrig’s disease). ALS is a fatal 
neurodegenerative disease characterized by progressive motor neuron death. Mutations in 
the FUS gene cause about 4% of familial ALS (FUS ALS). Mutated FUS protein 
mislocalizes from the motor neuron nucleus to the cytoplasm and forms inclusions in the 
cytoplasm. It is unclear how FUS mislocalization induces motor neuron dysfunction and 
degeneration. This dissertation research was designed to investigate the physiological 
functions of FUS in the nucleus, with a purpose to shed light on the pathogenesis of FUS 
ALS. Using biochemical and cell biology approaches, we revealed that there are two 
functionally distinct pools of FUS inside the nucleus. A portion of FUS is bound to active 
chromatin domains and is involved in gene transcription regulation. ALS mutations 
significantly decrease FUS chromatin binding. We further discovered chromatin binding 
requires FUS oligomerization, which is mediated by an intrinsically disordered QGSY 
(glutamine-glycine-serine-tyrosine) -rich region in FUS.  
Using confocal microscopy and an in vitro FUS oligomerization assay, we 
identified chromatin-associated nuclear RNAs as the trigger of FUS oligomerization. We 
further discovered that the RNA binding ability of FUS is also required for the 
cytoplasmic inclusion formation, which does not require the QGSY-rich region. By 
exchanging localizations of wild-type FUS and mutant FUS, we demonstrated that 
subcellular localization and RNAs play a more important role than ALS mutations in 
determining distinct FUS distribution and organization in different cellular 
compartments. 
By knocking down protein arginine methyltransferase gene and using methylation 
inhibitor treatment, we found that a post-translational modification of FUS—arginine
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methylation—can regulate FUS chromatin binding. Suppression of arginine methylation 
restored mutant FUS binding to active chromatin domains. Altogether, we revealed the 
distribution-related FUS physiological functions in the nucleus and identified a potential 
way to reverse the destructive effect of ALS mutations on wild-type FUS.   
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Chapter 1: Background and Introduction 
Fused in Sarcoma (FUS) is an RNA binding protein implicated in the motor 
neuron degenerative disease—amyotrophic lateral sclerosis (ALS). Mutations in the FUS 
gene cause a subset of familial ALS (hereditary ALS) [1, 2]. The name of FUS comes 
from a fusion gene, which contains part of the FUS gene, identified in 1993 to cause 
liposarcoma, a mesenchyme-derived cancer [3, 4]. The physiological function of the FUS 
protein itself is not fully understood. This dissertation research was designed to 
investigate the physiological role of FUS, with a purpose to shed light on the 
pathogenesis of ALS, by using biochemical and cell biology approaches. 
Amyotrophic lateral sclerosis 
ALS, also called Lou Gehrig’s disease in the United States, is a fatal motor 
neuron degenerative disease. Although categorized as a rare disease, ALS is the most 
common motor neuron disease. The prevalence of ALS in the United States is 3.9 in 
100,000 people in 2011 [5]. ALS is a very devastating disease and the patients typically 
pass away in 2-5 years after diagnosis [6]. The peak age of the diagnosed patients is 
around 60 years [6]; thus ALS is a late onset disease. Because of its fatality and late 
onset, ALS puts a heavy burden on the families of ALS patients and the society. In the 
summer of 2014, ALS caught public attention through a viral social media phenomenon, 
the ice-bucket challenge. 
 ALS is currently not curable. Thesole medication approved by the FDA for the 
ALS treatment is Riluzole, but it extends the life of ALS patients only for several months 
[7]. Other treatments for ALS are simply relieving the symptoms and improving the 
quality of life for the patients. These symptomatic treatments include medications to 
alleviate pain and emotional instability, physiotherapies to improve weakened muscles, 
and nutrition adjustment to compensate reduced food intake and hypermetabolism [6].  
ALS is characterized by both upper and lower motor neuron degeneration. Pure 
upper or lower motor neuron degeneration is diagnosed as different diseases, for example 
primary lateral sclerosis (PLS) that mainly involves upper motor neuron degeneration [8] 
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and spinal muscular atrophy (SMA) that primarily affects lower motor neurons [9]. 
Upper motor neurons carry information from the motor cortex to the spinal cord and 
lower motor neurons carry information from the spinal cord to voluntary muscles. 
Spasticity is a typical ALS symptom resulting from upper motor neuron degeneration. 
Muscle weakness, the most publicly recognized ALS symptom, is a consequence of 
lower motor neuron degeneration [6]. Reduced motor neuron numbers in the motor 
cortex and the spinal cord were detected in postmortem ALS patients.  
Motor neuron degeneration in ALS 
What causes motor neuron death in ALS is still a mystery. Both genetic and 
environmental factors contribute to the ALS pathogenesis. There are about 10% of all 
ALS cases are familial ALS [10], meaning gene mutations are the culprits for them. The 
majority of ALS cases, about 90%, are sporadic, meaning their disease-causing factors 
are not clear. Environmental factors are the main suspects in sporadic ALS cases. These 
environmental factors include life styles, e.g., smoking, unhealthy dietary, and lack of 
exercise; occupational risk factors, e.g., brain trauma in athletes and military personnel 
and toxins or viruses exposure in certain professions; and medical conditions such as 
metabolic diseases, cancer, and neuroinflammation [11]. It is noted that the genetic 
factors also play an important role in many cases of sporadic ALS. Further investigation 
is needed to determine the specific mechanisms by which the above causal or risk factors 
induce motor neuron dysfunction and degeneration. 
At the cellular level, an increasing amount of evidence supports that motor 
neurons die in a non-cell-autonomous fashion in ALS. The neighboring cells of motor 
neurons, most of the time glial cells, also contribute to their demise. Those glial cells are 
also susceptible to the causal or risk factors of ALS. The evidence of the non-cell-
autonomous mechanism mainly comes from the study of cell-type specific expression of 
mutant proteins in mice and the co-culture of healthy motor neurons with sick glial cells. 
In transgenic mice, expression of mutant SOD1, an ALS-causing protein, in motor 
neurons alone did not produce ALS-like phenotypes [12, 13] whereas expression in all 
cell types did [14, 15]. In the co-culture experiments, mutant SOD1 carrying or ALS 
patients derived astrocytes killed healthy motor neurons [16, 17].  In mutant SOD1 
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expressing mice, motor neuron-specific silencing of the mutant gene delayed the disease 
onset but had no effect on the disease progression [18-20], suggesting that the effects of 
ALS causal factors on motor neurons and glial cells have different contributions to the 
course of motor neuron degeneration.  
For the motor neuron itself, the direction of its degeneration, from the cell body to 
the axon (dying forward) or from the axon to the cell body (dying back), is still under 
debate. The main evidence of the dying back mechanism comes from the observation that 
the impaired neuromuscular junctions were observed prior to motor neuron loss in ALS 
mouse models [21, 22]. But the prevailing mechanism is dying forward, mainly because 
of the experimental observation that motor neurons die through programmed cell death in 
ALS mouse model [23] and that misfolded proteins in motor neurons spread “forward” 
along the anterograde axonal transport [24]. Another piece of evidence arguing against 
the dying back mechanism is the fact that both upper and lower motor neurons die at 
about the same rate in ALS [6].  
At the molecular level, a variety of mechanisms for motor neuron loss have been 
proposed. These include glutamate receptor-mediated excitotoxicity, oxidative stress 
induced structural damage, protein aggregation, impaired axonal transport, 
neuroinflammation, and aberrant RNA metabolism [25]. Various therapeutic 
interventions based on these molecular mechanisms are currently under development [26, 
27]. Riluzole, the only drug in the market, is a suppressor of glutamate receptors to 
dampen their excitability [28, 29]. But the overall drug development for ALS is much 
slower than for other diseases, largely due to the still-limited knowledge about the 
molecular pathways towards motor neuron degeneration. 
Since the mutated genes in more than half of familial ALS cases have been 
identified so far, a good start point to unravel the molecular pathogenesis of familial ALS 
is to study their physiological functions and pathological properties. Because of the 
shared disease phenotypes of familial ALS and sporadic ALS, the finding in familial ALS 
study will also be of great value in understanding the pathogenesis of sporadic ALS. 
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Genes underlying familial ALS  
The first ALS gene encoding Cu/Zn superoxide dismutase (SOD1) was identified 
in 1993 [30]. Mutations in the SOD1 gene cause about 20% of all familial ALS cases 
[10].  The second major ALS gene encoding TAR DNA-binding protein 43 kDa (TDP-
43) was identified in 2008 [31]. Mutations in the TDP-43 gene cause about 4% of 
familial ALS cases [10]. A year later, the FUS gene, mutations in which also cause about 
4% of familial ALS cases [10], was identified [1, 2]. Both TDP-43 and FUS are RNA 
binding proteins. The identification of them opened a new window to study ALS 
pathogenesis: RNA metabolism. In 2011, the ALS gene accounting for the largest portion 
of familial ALS cases was identified: C9orf72 [32, 33]. Mutations in C9orf72 cause about 
40% of all familial ALS cases [10]. The function of the protein product of C9orf72 is yet 
to be identified. 
Mutations in the SOD1, TDP-43, and FUS genes mostly take place in the coding 
region and result in single amino acid substitutions in their protein products. A small 
number of mutations also result in carboxyl-terminal (C-terminal) deletions of FUS and 
TDP-43 [34]. In contrast, mutations in C9orf72 do not change its coding sequence, but 
increase the number of hexanucleotide (GGGGCC) repeats in the first intron [32, 33]. In 
normal control, the first intron of C9orf72 contains less than 23 GGGGCC repeats. In 
ALS patients, the number of repeats increases to hundreds or more [32, 33]. The 
expanded GGGGCC repeats in ALS patients can be transcribed into repetitive RNAs [32, 
33], thus C9orf72 mutation also involves RNA metabolism.  
Three potential disease-causing mechanisms have been proposed for C9orf72 
mutation: 1) the reduction of C9orf72 protein level [32, 33] may be harmful for motor 
neurons; 2) repetitive GGGGCC RNAs sequester essential RNA binding proteins that are 
critical for motor neuron health; and 3) GGGGCC RNA repeats can be translated through 
an unconventional repeats-associated non-ATG (RAN) translation mechanism [35, 36] 
and the translated dipeptide repeats are toxic to motor neurons [37, 38]. Interestingly, the 
toxicity of dipeptide repeats involves their accumulation in the nucleoli and the 
disturbance of pre-mRNA splicing and ribosomal RNA biogenesis [38]. The study of 
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C9orf72 disease-causing mechanism further strengthened the idea that aberrant RNA 
metabolism may play a critical role in ALS pathogenesis.  
Additional genes have also been identified in rare forms of familial ALS. Four 
such genes also involve RNA metabolism: SETX encodes a potential DNA/RNA helicase 
[39]; ANG encodes a ribonuclease which cleaves tRNA and stimulates rRNA synthesis 
[40]; HNRNPA1 encodes a heterogeneous nuclear ribonucleoprotein which functions in 
various RNA metabolism processes [41]; and TAF15 encodes TATA box binding protein 
associated factor which plays a role in transcription regulation [42]. Therefore, RNA 
metabolism is an emerging field for multiple forms of familial ALS.  
ALS genes and sporadic ALS 
ALS genes are also implicated in sporadic ALS. Mutations in ALS genes such as 
SOD1, TDP-43, FUS and C9orf72 were also found in sporadic ALS [43-45], indicating 
that familial and sporadic ALS may share the same pathological pathways. More 
importantly, wild-type protein products of the ALS genes with abnormal properties or 
behaviors have been widely observed in sporadic ALS. For example, oxidized and 
misfolded wild-type SOD1, which possesses many mutant SOD1 properties, has been 
detected in a large number of sporadic ALS cases [46-48]. Wild-type or truncated TDP-
43 are the major components of ubiquitin-positive inclusions observed in the motor 
neurons of most of sporadic ALS patients [49, 50]. FUS positive inclusions have also 
been reported in sporadic ALS [51] and FUS protein is involved in multiple forms of 
sporadic ALS mediated by SOD1, TDP-43, or C9orf72 [52-54]. The implication of ALS 
genes in sporadic ALS strengthened the importance of familial ALS research in revealing 
the overall etiology of ALS.  
FUS in ALS 
FUS is an RNA binding protein predominantly localized in the nucleus. ALS 
mutations result in FUS retention in the cytoplasm and the formation of FUS inclusions 
in the cytoplasm [1, 2]. FUS has multiple functions in the nucleus [44]. However it is 
unclear how FUS is deployed to fulfill its multiple roles or what are the consequences of 
ALS mutations on FUS nuclear functions. FUS inclusions colocalize with stress granule 
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proteins [55, 56] in the cytoplasm. Stress granules are temporary RNA/protein complexes 
that ensure cell survival under harsh conditions [57]. But it is still unknown whether 
mutant FUS affects cell stress response. The Holy Grail question: is nuclear loss of FUS 
or cytoplasmic accumulation of FUS inclusions responsible for motor neuron 
degeneration is still under debate.  
i)	Loss‐of‐function	mechanism	
Most of ALS mutations in FUS are clustered in its C-terminal nuclear localization 
sequence (NLS) [34]. Mutations reduce the binding affinity of FUS NLS to transportin1 
[58, 59], the nuclear envelop protein that is responsible for importing cytoplasmic 
synthesized proteins into the nucleus. Therefore a direct consequence of most FUS ALS 
mutations is FUS cytoplasmic retention, which subsequently results in nuclear FUS 
deficiency.  
The reported roles of FUS in the nucleus include DNA damage repair [60-62], 
transcription regulation [63-65], and splicing regulation [63, 64, 66]. The immediate 
suspicion of the consequences of a nuclear FUS deficiency is the disturbance of these 
cellular activities that FUS participates in. Indeed, FUS knock-out induced a high 
incidence of genomic instability in mice [62]. In mouse brain and cultured cells, FUS 
depletion changed the expression level of hundreds of genes and the splicing pattern of 
hundreds of mRNAs [63, 64]. However, it is unknown whether these consequences of 
nuclear FUS deficiency contribute directly to motor neuron degeneration. The FUS 
knock-out mice died shortly after birth with no clear neuron-related phenotypes [62]. 
Loss of RNA metabolism-regulating protein has been proved able to cause motor 
neuron death. SMA is a lower motor neuron degenerative disease caused by deletion or 
nonsense mutations of a gene named survival of motor neuron (SMN) [9].  SMN 
regulates small nuclear RNPs assembly which is crucial for mRNA splicing in the 
nucleus [67].  
Another potential loss-of-function mechanism involves cytoplasmic FUS. 
Although wild-type FUS is primarily localized in the nucleus, a small amount of wild-
type FUS also exists and carries out certain functions in the cytoplasm. This is 
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particularly true in the neuronal cells [68-70]. FUS has been reported to be important for 
mRNA transport in the dendrites and protein local translation in the synapsis [71, 72]. In 
this scenario, ALS mutations may change the conformation of FUS and impair its 
function in local translation regulation [73]. Disturbed dendritic local translation has also 
been proved to cause neuronal disorders. Fragile X syndrome is a neural developmental 
disease caused by mutations in fragile X mental retardation (FXR) gene [74, 75]. The 
protein product of the FXR gene is critical for mRNA transport in the dendrites [76, 77].  
ii)	Gain‐of‐function	mechanism	
The cytoplasmic-retained nonresident FUS mutants may cause motor neuron 
dysfunction and degeneration through gain-of-toxic-function mechanisms. Cytoplasmic 
FUS inclusions are a convenient suspect because proteinaceous inclusions are commonly 
observed in a spectrum of neurodegenerative diseases. Inoculation of the components of 
neurodegenerative diseases related proteinaceous inclusions, for instance β-amyloid [78], 
Tau [79], or α-synuclein [80], induced similar disease phenotypes in mice. These results 
further intrigue researchers to incline to the gain-of-function mechanism. 
However, most of the toxic inclusions are composed of misfolded proteins in a 
cross-β-sheet structure [81-85], the structural basis of amyloidal aggregation. No 
amyloidal aggregation has been detected in FUS inclusions [86, 87]. An intermediate 
product of amyloidal aggregation, amyloidal oligomers, are considered the real culprit of 
neuronal death in various neurodegenerative diseases in recent years [88, 89]. But till 
now no toxic FUS oligomers has been reported. These facts require researchers to be 
cautious when interpreting FUS mutants toxicity in model organisms.  
A distinct property of FUS inclusions compared to the amyloidal aggregates is its 
colocalization with stress granule proteins [55, 56]. Stress granules contain mRNAs and 
RNA binding proteins from the suspended protein translation apparatus [57]. It is still a 
mystery how mutant FUS is incorporated into stress granules and whether mutant FUS 
disturbs normal stress granule response. It is conceivable that persistent FUS inclusions 
sequester and immobilize essential stress granule proteins, thus weakening the normal 
stress response and resulting in motor neuron degeneration in the long run.  
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Transgenic expression of FUS mutants in rodents also gave confusing results. 
Most of FUS transgenic models reproduced some ALS phenotypes, including low 
viability, motor defects, and alteration of motor neuron dendritic structure [73, 90, 91]. 
But the most prominent pathological features of ALS with FUS mutations—FUS 
inclusions and motor neuron loss—were not detected in these models [73, 90, 91].  
Two recent reports of FUS gain-of-function in the nucleus further complicated the 
understanding. One reported that a point mutation in FUS resulted in its intranuclear 
aggregation and caused ALS [92]. The other reported that over-expressing FUS in 
cultured cortical neuron nucleus, not cytoplasm, induced neuron death [93].  
At this time, it remains debatable whether a loss-of-function mechanism or a gain-
of-function mechanism alone is the sole culprit of motor neuron degeneration in familial 
ALS with FUS mutations. It is possible that both can contribute to the pathogenesis. 
Before we make further speculation, it is better to re-examine the physiological function 
of FUS in details and rethink how ALS mutations in FUS cause such a detrimental effect 
on motor neurons. Below I will describe the domain structure of the FUS protein and 
briefly discuss their potential involvement in the physiological or pathological activities 
of FUS. 
FUS domain structure 
The amino-terminus (N-terminus) of FUS contains an intrinsically disordered 
sequence [94]. The composition of amino acids in this sequence is simple and limited to 
certain types; thus it is also called a low complexity domain [95]. The disordered 
sequence can be divided into two regions (Figure 1.1). From amino acid 1 to amino acid 
164 is located a QGSY-rich region which is mainly comprised of glutamine, glycine, 
serine, and tyrosine. From amino acid 165 to amino acid 284 a glycine-rich region, which 
contains mainly glycine, is located.  
FUS N-terminus was also predicted as a prion-like domain based on its 
glutamine/glycine-rich feature [96]. The word prion was coined to describe a misfolded 
protein that can convert normal protein conformation to a pathological conformation and 
drive the formation of fibrilar aggregates. Accordingly, one of the properties of the prion-
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like domain is aggregation-prone [97]. Indeed, purified FUS protein formed fibrilar 
aggregates and the prion-like domain played an essential role in this process [98]. A 
study of FUS low complexity domain found that the FUS N-terminus itself formed 
fibrilar aggregates at high concentration [95, 99, 100]. Because misfolded protein 
aggregation has long been blamed for neuronal death in many neurodegenerative 
diseases, the aggregation-prone property of the FUS N-terminus caught much attention 
when discussing gain-of-function mechanisms.  
After the disordered sequence, a RNA recognition motif (RRM) is located from 
amino acid 285 to amino acid 370 (Figure 1.1). The structure and RNA binding 
properties of FUS RRM have been characterized by our lab [101]. A zinc finger domain 
is located from amino acid 371 to amino acid 494, which contains a zinc finger motif 
(ZnF) flanked by two arginine-glycine-glycine (RGG) repeat regions. Both the RRM and 
zinc finger domain can bind RNA; they define the RNA binding protein identity of FUS. 
In a FUS pull-down and RNA sequencing study, RNAs from more than 5,000 human 
genes and RNAs from more than 8,000 mouse genes were identified as targets for FUS 
binding [64]. The two gene pools are largely overlapped (69%) [64], suggesting FUS 
plays fundamental role in RNA metabolism.  
At the very C-terminus of FUS is located a NLS (Figure 1.1). FUS NLS is a non-
classical NLS which is called PY-NLS because of its proline/tyrosine pair [102]. The PY-
NLS of FUS was identified by our lab [55] and other labs [103-105].  We and others 
determined the structure of FUS PY-NLS and its complex with transportin 1 [58, 59]. 
Both studies found that ALS mutations dramatically reduced the binding affinity of FUS 
NLS to transportin 1 [58, 59]. 
Besides these major sequence features, there are three RGG repeat regions 
interspersed between functional motifs (Figure 1.1). The first RGG repeat region (RGG1) 
is located in the glycine-rich region. The second RGG repeat region (RGG2) is located 
between the RRM and the ZnF and the third one (RGG3) is located after the ZnF and 
before the NLS. Because of the positive charges of arginine side chain and the negative 
charges of nucleic acid, it is believed that RGG repeats can significantly enhance the 
binding affinity of RRM or ZnF to RNA. Additionally, RGG repeats are typical 
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substrates of protein arginine methyltransferases (PRMTs) [106]. FUS has been reported 
to be arginine-methylated by PRMT1 [107, 108].  
In this dissertation research, we revealed how nuclear FUS is deployed for its 
multiple functions inside the nucleus and how ALS mutations disturb this process 
(Chapter 3). The nuclear FUS is separated into two functionally distinct pools: 
chromatin-bound and non-chromatin-bound. Only chromatin-bound FUS can regulate 
gene transcription. The requirement for FUS chromatin binding is oligomerization (or 
self-assembly). Interestingly, FUS oligomerization is mediated by the QGSY-rich region, 
part of the predicted prion-like domain. ALS mutations significantly decrease FUS 
chromatin binding. We identified RNA molecules that are essential for FUS organization 
in different cellular compartments: nucleus and cytoplasm (Chapter 4). In the nucleus, 
chromatin-associated RNAs initiate FUS oligomerization; in the cytoplasm, RNA binding 
ability is required for FUS inclusion formation. We also discovered arginine methylation 
in the RGG repeats that can regulate FUS chromatin binding (Chapter 5). Suppression of 
arginine methylation restored mutant FUS chromatin binding. Together, we revealed the 
distribution-related FUS physiological functions and their regulation in the nucleus and 
identified a potential way to reverse the effect of ALS mutations on FUS. 
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Figure 1.1 FUS domain structure 
QGSY, QGSY-rich region; G, glycine-rich region; RRM, RNA recognition motif; zinc 
finger, zinc finger domain; NLS, nuclear localization sequence; RGG, arginine-glycine-
glycine repeats. 
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Figure 1.1 FUS domain structure 
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Chapter 2: Materials and Methods 
Plasmids 
The pEBG-FUS (GST-FUS) and pEGFP-C3-FUS plasmids were constructed in a 
previously published study [55]. Truncated FUS coding sequences were amplified by 
PCR from pEBG-FUS or pEGFP-C3-FUS R521G plasmid template and subcloned into 
pEBG (restriction sites: Bam HI and Kpn I), pEGFP-C3 (restriction sites: Bgl II and Kpn 
I), pDsRed-Monomer-C1 (Clontech, restriction sites: Kpn I and Bam HI), and pDsRed2-
C1 (Clontech, restriction sites: Bgl II and Kpn I) vectors. pEGFP-C3-FUS-NES and 
pEGFP-C3-FUS R495X-NLS were constructed in another previously published study 
[109]. Firefly luciferase reporter plasmid was constructed by subcloning the MnSOD 
promoter region (-2947-+24) into pGL3 reporter plasmid at the site upstream of 
luciferase coding sequence [110]. Renilla luciferase reporter plasmid was purchased from 
Promega. E1A minigene plasmid was constructed by cloning of the E1A genomic 
sequence into the pcDNA1.1 eukaryotic expression vector [111]. Insulin receptor 
minigene was constructed by cloning the insulin receptor genomic sequence into pSG5 
vector [112]. LMNA Mut minigene was constructed by cloning the LMNA genomic 
sequence from HGPS patients, which have a point mutation in exon 11 of the LMNA 
gene, into βglo3S vector [113]. SMN2 minigene plasmid was constructed by cloning the 
SMN2 genomic sequence into pCI vector and Tau minigene plasmid was constructed by 
cloning the Tau genomic sequence into pSVIRB vector. pCMV2B-PRMT1 plasmid is a 
gift from Dr. Weimin Gong at the Institute of Biophysics, Chinese Academy of Sciences.  
Antibodies and reagents 
FUS antibody (sc47711), Sp1 antibody (sc-59), SOD1 antibody (sc-11407), 
Histone H1 antibody (sc-10806), GST antibody (sc-139), DsRed antibody (sc-33353), 
DsRed2 antibody (sc-101526), and GFP antibody (sc-8334) were purchased from Santa 
Cruz Biotechnology. Histone H3 antibody (catalog no. 9715) was purchased from Cell 
Signaling Technology. Methylarginine antibody (catalog no. ab412) was purchased from 
Abcam. PRMT1 antibody (catalog no. 07-404) and Benzonase (catalog no. 70746) were 
purchased from EMD Millipore. Micrococcal nuclease was purchased from New England 
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Biolabs (catalog no. M0247). 5,6-Dichlorobenzimidazole 1-β-D-ribofuranoside (DRB, 
catalog no. 1916) and Adenosine, periodate oxidized (AdOx, catalog no. 7154) were 
purchased from Sigma-Aldrich. RNase-free DNase (catalog no. M6101) was purchased 
from Promega. Proteinase K (catalog no. P8102) was purchased from New England 
BioLabs. RNase A (catalog no. 19101) and QIAquick PCR Purification Kit (catalog no. 
28104) were purchased from QIAGEN. PRMT1 siRNA (SMARTpool: siGENOME 
PRMT1 siRNA) was purchased from GE Healthcare Dharmacon. 
Cell culture and transfection 
HEK cells were grown in Dulbecco’s Modified Eagle’s Medium (Life 
Technologies, catalog no. 11965) plus 10% fetal bovine serum (Sigma-Aldrich, catalog 
no. F2442) and 1% Penicillin-Streptomycin (Sigma-Aldrich, catalog no. P4333). Cell 
transfection was performed using 0.5 μg plasmid for cells cultured in 6-well plates 
(unless specifically noted) following the standard protocol as previously described [55]. 
Cells were subjected to experiments 48 hours after transfection unless otherwise noted. 
For chromatin salt elution assay, we used HEK cells with doxycycline-inducible GFP-
FUS, GFP-FUS R521G, and GFP-FUS R495X expression as described in [114]. Briefly, 
inducible HEK cells were cultured, induced with doxycycline and subjected to 
experiments 48 hours after induction. 
Punch skin biopsies were obtained after informed consent from symptomatic 
familial ALS patients carrying the R521G FUS mutation as previously published [110]. 
The study was approved by the Institutional Review Board of the University of Kentucky 
and details of the patients were described in [110]. Fibroblast cells were generated from 
the skin biopsies and cultured in Minimum Essential Medium Eagle (Sigma-Aldrich, 
catalog no. M5650) plus 20% FBS, 2 mM L-glutamine (Sigma-Aldrich, catalog no. 
G7513) and 1% Penicillin-Streptomycin.  
Chromatin-bound protein isolation 
Cells were suspended in radioimmunoprecipitation assay (RIPA) buffer (EMD 
Millipore, catalog no. 20-188) containing protease inhibitor cocktail (Sigma-Aldrich, 
catalog no. P8340, 1:1000), 200 μM phenylmethanesulfonylfluoride (PMSF) and 1 mM 
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sodium orthovanadate. Cells were homogenized with a 23G needle. After 20 min 
incubation on ice, cell lysates were centrifuged at 1,000 x g for 10 minutes at 4°C. The 
supernatants were removed and the pellet was resuspended with RIPA buffer 
supplemented with 0.3% SDS and 250 U/ml Benzonase. Pellet suspensions were 
incubated on ice for 10 minutes and centrifuged again at 1,000 x g for 10 minutes at 4°C. 
The supernatant from the second centrifugation contained most of the chromatin-bound 
proteins. 
 Alternatively, the Subcellular Protein Fractionation Kit from Pierce (catalog no. 
78840) was used following the manufacturer’s instructions. Cell lysates were separated 
into cytoplasmic, membrane, nuclear soluble, chromatin bound and cytoskeletal fractions.  
Isolation of active chromatin using salt elution 
Active and inactive chromatin domains were separated following a previously 
published salt elution protocol [115]. Briefly, cells were harvested, washed and incubated 
in nucleus isolation buffer (10 mM HEPES, pH 7.9; 10 mM KCl; 1.5 mM MgCl2; 0.34 M 
Sucrose; 10% Glycerol; 1 mM DTT; 0.1% Triton X-100; 1:1000 protease inhibitor 
cocktail) on ice for 8 minutes. After 1,300 x g centrifugation, nuclei were precipitated in 
the pellet and cytoplasm was retained in supernatant (S1). Purified nuclei were 
resuspended in separation buffer containing 2,000 gel units/ml Micrococcal nuclease and 
1 mM CaCl2. The nuclei suspension was incubated at 37°C for 10 minutes and the 
reaction was stopped by adding 2 mM EGTA. The supernatant (S2) was removed and the 
digested nuclei were eluted with 150 mM NaCl at 4 °C for 2 hours (E1) and with 600 
mM NaCl at 4 °C overnight (E2) sequentially. The remnant (P) from 600 mM NaCl 
elution was resuspended with 2% SDS loading buffer. The S1, S2, E1, E2 and P fractions 
were subjected to SDS-PAGE followed by Western blot. 
SDS polyacrylamide gel electrophoresis (SDS/PAGE) and Western blot 
Cell extracts, fractions, and eluates were mixed with loading buffer containing 2% 
SDS and heated at 95 °C for 5 minutes. SDS-PAGE was performed using 10% or 4-15% 
polyacrylamide gel to resolve proteins. After being transferred to a nitrocellulose 
membrane, the membrane was blotted with appropriate primary antibodies in TBST with 
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5% milk, target proteins were visualized using HRP-linked secondary antibodies (GE 
Healthcare) and ECL HRP substrate (Thermo Scientific, catalog no. 34078). 
Immunostaining and fluorescence confocal microscopy 
Cells were seeded on gelatin-covered 18 mm glass coverslips in 12-well plates 
and transfected with 0.25 μg plasmid. 24 hours after transfection, cells were fixed with 
4% paraformaldhyde at 37 °C for 15 minutes and permeabilized with 0.25% Triton at 
room temperature for 5 minutes. Permeabilized cells and nuclei were blocked with 10% 
bovine serum albumin (BSA) at 37 °C for 1 hour and immunostaining was performed 
with primary antibodies at 4 °C overnight and secondary antibodies at 37 °C for 1 hour. 
Both primary and secondary antibodies were diluted in 3% BSA in 1x PBS. During 
secondary antibody incubation, 2 μg/ml DAPI was added to stain nuclear DNA. Cells 
were subsequently mounted with Vectashield mounting medium (Vector Laboratories, 
catalog no. H-1000) and observed under a Nikon A1 confocal microscope. 
Luciferase reporter gene assay 
0.05 μg firefly and 0.005 μg renilla luciferase reporter plasmids were transfected 
along with pEGFP-C3-FUS into HEK cells. 48 hours later, luciferase assay was 
performed with the Dual-Luciferase Reporter Assay System from Promega (catalog no. 
E1910) following the manufacturer’s instructions.  
Reverse transcription and real-time PCR 
Total RNA was extracted with TRIzol LS Reagent (Life Technologies, catalog 
no. 10296-010) following the manufacturer’s instructions. Total RNA concentration was 
determined by NanoDrop 1000 spectrophotometer (Thermo Fisher Scientific). 5 μg total 
RNA was incubated with 1 μl RNase-Free DNase (Promega, catalog no. M6101) in 20 μl 
reactions at 37°C for 1 hour. 2 μl DNase-treated total RNA was used to synthesize first 
strand cDNA with SuperScript III First-Strand Synthesis System (Life Technologies, 
catalog no. 18080-051) using oligo(dT) primer. 2 μl cDNA was used for real-time PCR 
with Power SYBR Green PCR Master Mix (Life Technologies, catalog no. 4367659) 
using a Mx3005P qPCR System (Agilent Technologies, model no. 401513). Primers used 
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for SMYD3 real-time PCR are: sense: 5’-GGCAAACTGCAGCTACATCA-3’; anti-
sense: 5’-GTTGGCGTCGCATTCTTCTA-3’. 
Minigene splicing assay 
Total RNA extraction and first strand cDNA synthesis were carried as described 
above except the primers used here were gene-specific anti-sense oligos instead of 
oligo(dT). Primers used are: E1A sense:  5’- AGGTTGTTCACGTAGGCCGC-3’, anti-
sense 5’- AGCATGTTGAGCCGGGCAAGT-3’; insulin receptor sense: 5’-
TAATACGACTCACTATAGGGC-3’, anti-sense: 5’-
GCTGCAATAAACAAGTTCTGC-3’; LMNA Mut sense: 5’-
GCTTCTGACACAACTGTGTTCACTAGC-3’, anti-sense: 5’-
GCAGTTCTGGGGGCTCTGG-3’; SMN2 sense: 5’-GGTGTCCACTCCCAGTTCAA-
3’, anti-sense: 5’-GCCTCACCACCGTGCTGG-3’, special anti-sense for the first strand 
cDNA synthesis: 5’-TGGTTTGTCCAAACTCATCAA; and Tau sense: 5’-
CAGCTACAGTCGGAAACCATCAGCAAGC-3’, anti-sense: 5’-
CACCTCCAGTGCCAAGGTCTGAAGGTCA-3’.  The splicing products were resolved 
by 1% agarose gel electrophoresis followed by ethidium bromide staining.  
GST pull-down and mass spectrometry 
GST-tagged FUS 1-164, FUS 165-526, and full-length FUS were expressed in 
HEK cells. GST pull-down was performed using glutathione Sepharose 4 B (GE 
Healthcare, cat no. 17-0756-01) as previously described [116]. The pull-down samples 
were digested with trypsin and the tryptic peptides were subjected to shot-gun proteomics 
analysis as previously described [117]. Briefly, the tryptic peptides were analyzed by LC-
MS/MS using an LTQ Velos Orbitrap mass spectrometer (Thermo Fisher Scientific, 
Waltham, MA) coupled with a Nano-LC Ultra/cHiPLC-nanoflex HPLC system 
(Eksigent, Dublin, CA) through a nano- electrospray ionization source. Tandem MS/MS 
data were acquired using CID fragmentation of selected peptides during the information-
dependent acquisition. The LC-MS/MS results were subjected to protein identification 
and acetylation sites determination using ProteomeDiscoverer 1.3 software (Thermo 
Fisher Scientific) and MASCOT server.  
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Chromatin-bound protein isolation for native gel electrophoresis 
To preserve the native state of proteins, HEK cells were lysed in a detergent-free 
lysis buffer (50 mM Tris·HCl, pH 7.4, 150 mM NaCl, 1 mM EDTA) plus protease 
inhibitor cocktail (1:1000), 200 μM PMSF, and 1 mM sodium orthovanadate by passing 
through a 23G needle several times. After centrifugation at 1,000 x g at 4 °C, chromatin 
and cell debris were in the pellet and non-chromatin-bound proteins were in the 
supernatant. The pellet was resuspended in the detergent-free lysis buffer and chromatin-
bound proteins were released by breaking chromatin DNA with sonication (Sonic Vibra-
Cell Ultrasonic Processor VCX130PB, amplitude 40, 15 x 1 second cycles). After 
centrifugation again at 1,000 x g at 4 °C, chromatin-bound proteins were retained in the 
supernatant. Both chromatin-bound proteins and non-chromatin-bound proteins were 
subjected to 8% native polyacrylamide gel electrophoresis and Western blot as described 
below. 
Native gel electrophoresis 
The chromatin-bound and non-chromatin-bound proteins (50 μl) were mixed with 
10 μl of 6X loading buffer (350 mM Tris-HCl, pH 6.8, 30% Glycerol, 0.24% SDS, 0.02% 
Bromphenol blue). Samples were loaded on a 8% polyacrylamide gel soaked in 
detergent-free running buffer (25 mM Tris, 192 mM Glycine). The stacking was 
performed at 75 Volts and the separating was performed at 120 Volts. Subsequently, the 
gel was incubated with transfer buffer (25 mM Tris, 192 mM Glycine, 10% Methanol) 
supplemented with 0.25% SDS at 70 °C for 10 minutes. After the denaturation step, the 
gel was ready for transferring and Western blot following the same procedure as 
described earlier.  
Initiation of FUS oligomerization by chromatin content 
Different amount of chromatin content, which was released by sonicating the re-
suspended chromatins in the detergent-free lysis buffer, was incubated with the non-
chromatin-bound sample for 20 minutes on ice. The mixture was then subjected to native 
gel electrophoresis and Western blot.  
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 During the incubation of the chromatin content and the non-chromatin-bound 
sample, 50 U/ml RNase-free DNase or 1 ng/ml RNase A was added in the mixture. After 
incubation, the effect of DNase or RNase on the oligomerization of non-chromatin-bound 
FUS was assessed by native gel electrophoresis. The nucleic acid contents in each sample 
were purified with QIAquick PCR Purification Kit after proteinase K digestion and 
subjected to agarose gel electrophoresis.  
Formaldehyde crosslinking 
The chromatin-bound and non-chromatin-bound proteins were prepared as above 
and separately incubated with formaldehyde at a final concentration of 1% at room 
temperature with rocking for 10 minutes. Crosslinking was quenched by adding glycine 
to a final concentration of 137.5 mM. The crosslinked samples were subjected to 12% 
SDS/PAGE followed by Western blot.  
Nuclear RNA extraction and the effect of nuclear RNA on FUS oligomerization 
Cells were harvested, washed and incubated in nucleus isolation buffer (10 mM 
HEPES, pH 7.9; 10 mM KCl; 1.5 mM MgCl2; 0.34 M Sucrose; 10% Glycerol; 0.1% 
Triton X-100) on ice for 8 minutes. Nuclei were isolated by 1,300 x g centrifugation and 
resuspended in 0.25 ml nucleus isolation buffer. Total nuclear RNA was extracted by 
0.75 ml TRIzol LS Reagent. 2 or 20 μg nuclear RNA was incubated with 50 μl non-
chromatin-bound extract at 4 °C overnight. These samples were subsequently subjected 
to native gel electrophoresis and Western blot. 
In vitro RNA binding assay 
FUS peptide coding sequences were subcloned into the pET22b plasmid 
(Novagen). FUS peptides were expressed in E.coli Rosetta cells (EMD Millipore) and 
purified with Ni2+ affinity chromatography and cation exchange column (GE Healthcare, 
catalog no. 17-5157-01). The RNA probe (5’-UUAGGGUUAGGGUUAGGGUUAGGG-
3’) was labeled with 5’-Cy3 (Invitrogen). Different concentrations of FUS peptides were 
incubated with 5 pmol RNA probes in 10 μl reaction buffer (20 mM Tris-HCl, pH 7.5; 
and 50 mM NaCl) on ice for 30 minutes. The mixtures were loaded on a 6% 
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polyacrylamide gel and run in ice cold TBE buffer at 100 Volts for 45 minutes. The gel 
was analyzed by ProteinSimple gel imaging system. 
FUS immunoprecipitation 
AdOx-treated, PRMT1 knocked-down, or PRMT1 over-expressing HEK cells 
were lysed in RIPA buffer containing protease inhibitor cocktail (1:1000), 200 μM PMSF 
and 1 mM sodium orthovanadate by passing through a 23S needle several times. After 
1,000 g centrifugation at 4 °C, the supernatants were pre-cleared with 50 μl of Protein G 
slurry at 4°C for 1 hour. Immunoreaction was performed with 2 μg FUS antibody in 500 
μl of supernatant at 4°C for 1 hour. The antigen-antibody complexes were enriched by 50 
μl Protein G at 4°C overnight, purified by RIPA buffer washing, and released by SDS 
loading buffer at 95 °C for 5 minutes. 
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Chapter 3: Self-assembled FUS Binds Active Chromatin and Regulates Gene 
Transcription 
Modified from the manuscript “Self-assembled FUS binds active chromatin and 
regulates gene transcription”, published in the Proceedings of the National Academy of 
Sciences of the United States of America. 2014. 111(50): 17809-17814. doi: 
10.1073/pnas.1414004111. The introduction was simplified for fluidity and the figures 
were reorganized. 
Introduction 
ALS is a progressive and fatal neurodegenerative disease characterized by motor 
neuron loss. The etiology underlying the disease is yet to be better understood. About 
10% of ALS cases are hereditary (familial ALS). Mutations in FUS, which is an RNA 
binding protein, are found to be responsible for a subset of familial ALS patients [1, 2].  
FUS is a multifunctional protein and has been reported to play a role in various 
aspects of RNA metabolism [44], including transcription regulation and alternative 
splicing. In familial ALS, most mutations are clustered in the C-terminal NLS of FUS 
and consequently cause the mislocalization of FUS protein from the nucleus to the 
cytoplasm and the accumulation of protein inclusions [55, 103, 104]. Such observations 
suggest two potential disease-causing mechanisms: loss of FUS normal function in the 
nucleus and gain of toxic function in the cytoplasm. It remains to be determined which 
mechanism plays a more critical role in the ALS etiology and the two mechanisms are 
not necessarily exclusive of each other.  
Although the mutations in the C-terminal NLS are critical to the cytoplasmic 
accumulation of mutant FUS, the N-terminal prion-like domain has been reported to be 
crucial for FUS aggregation in vitro and in yeast cells [98]. The prion-like domain 
consists of a QGSY-rich region (amino acids 1-164) and a glycine-rich region (amino 
acids 165-239). A missense mutation (G156E) in the QGSY-rich region has been found 
in familial ALS patients and has been reported to cause intranuclear aggregation of FUS 
[92]. However, the role of the QGSY-rich region in maintaining FUS intranuclear 
distribution and function under physiological conditions is unknown.  
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The physiological function of FUS in the nucleus remains to be fully understood. 
In this study, we found that a significant portion of nuclear FUS was bound to chromatin 
and that the ALS mutations dramatically decreased FUS chromatin binding ability. 
Functionally, chromatin binding is required for FUS transcription activation, but not for 
the regulation of alternative splicing. We further determined that the N-terminal QGSY-
rich region mediates FUS self-assembly in the nucleus of mammalian cells and that FUS 
self-assembly is essential for chromatin binding and transcription activation. In addition, 
RNA binding is also required for FUS self-assembly and chromatin binding. Together, 
our results suggest that a functional assembly of FUS in the nucleus under physiological 
conditions is different from the cytoplasmic inclusions found in cells harboring ALS 
mutations. These mutations cause of loss-of-function in the nucleus by disrupting FUS 
assembly and chromatin binding as well as transcriptional activities. 
Results 
FUS is bound to chromatin and ALS mutations reduce chromatin binding 
The wild-type FUS protein is known to be predominantly localized in the nucleus. 
We asked whether FUS is associated with chromatin. Chromatin-associated proteins in 
human embryonic kidney (HEK) cells were prepared by extraction with 0.3% SDS and 
250 U/ml Benzonase (see flow chart in Figure 3.1A). A significant amount of 
endogenous FUS was in the chromatin-bound (CB) fraction extracted by SDS and 
Benzonase (Figure 3.1A). As a control, histone H3 was also present in the CB fraction. 
The result provided the initial evidence that FUS may bind to chromatin. To confirm this, 
we employed an independent protocol to fractionate HEK cell lysate into cytoplasmic, 
membrane, nuclear soluble, chromatin bound and cytoskeletal fractions. The amount of 
chromatin-bound FUS was comparable to that in the nuclear soluble (NS) fraction 
(Figure 3.1B). Western blots of the nuclear soluble protein Sp1 and the chromatin-bound 
protein H3 are included to demonstrate the effectiveness of the fractionation method.  
Next, we tested whether the ALS mutations had an effect on FUS chromatin 
binding. Wild-type FUS and ALS mutants (R521G, Arg 521 mutated to Gly; R495X, Arg 
495 mutated to the stop codon, resulting in the deletion of the C-terminal 32 amino acids) 
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were expressed in HEK cells and the cell lysates were subjected to the fractionation as 
described above. The ALS mutations significantly decreased the chromatin-bound FUS 
as compared to the nuclear soluble FUS (Figure 3.2). Quantitative analysis confirmed that 
the ratio of chromatin-bound and nuclear soluble fractions decreased for the FUS ALS 
mutants (p < 0.02; Figure 3.2). Consistent with previous reports, the ALS mutations also 
increased the cytoplasmic portion of FUS.  
To shed light on the functional role of the chromatin-bound FUS, we further 
fractionated chromatin to determine to which chromatin domain FUS binds. Chromatin 
domains can be fractionated by limited nuclease digestion and gradient salt elution based 
on different architectural levels [115]. Transcriptionally active chromatin domains are 
loosely packed, therefore are easily digested by nuclease and eluted at lower salt 
concentration (Figure 3.3A; E1, 150 mM NaCl elution). Transcriptionally inactive 
chromatin domains are densely packed, therefore are more difficult to be digested and 
can only be eluted at a higher salt concentration (Figure 3.3A; E2, 600 mM NaCl 
elution). A significant amount of endogenous FUS was detected in the nuclear soluble 
(S2) and active chromatin (E1) fractions, whereas a lesser amount of FUS was detected in 
the inactive chromatin (E2) fraction indicated by Histone H1 immunoblot (Figure 3.3A). 
The DNA electrophoresis of S1, S2, E1 and E2 fractions are also shown in Figure 3.3A to 
confirm that E1 and E2 are active and inactive chromatin, respectively [115]. The results 
suggest that FUS may play a regulatory role in the transcriptionally active chromatin.  
The effect of the ALS mutations was also examined on the association of FUS 
with active chromatin. The level of FUS in active chromatin domains (E1) significantly 
decreased for the ALS mutations R521G and R495X as compared to wild-type FUS 
(Figure 3.3B). The quantitative results of the E1/S2 ratio are also shown in Figure 3.3B (p 
< 0.05 for R521G and p < 0.005 for R495X).  
The N-terminal QGSY-rich region is responsible for FUS chromatin binding 
To determine which domains of FUS are responsible for chromatin binding, we 
generated a series of GST-tagged FUS truncation constructs (Figure 3.4A). The 
chromatin-bound fraction was prepared with the SDS and Benzonase extraction method 
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as in Figure 3.1A. All N-terminal fragments (FUS 1-164, 1-284, 1-370, and 1-494) were 
detected in the chromatin-bound fraction (Figure 3.4B). In contrast, none of C-terminal 
fragments lacking the N-terminal QGSY-rich domain (FUS 165-526, 285-526, 371-526, 
and 495-526) was detected in the chromatin-bound fraction. The results suggest that the 
N-terminal QGSY-rich region is both sufficient and required for FUS chromatin binding. 
Interestingly, deleting the N-terminal QGSY-rich region also significantly 
changed the intranuclear distribution of FUS. Full-length FUS displays a punctate pattern 
inside the nucleus (Figure 3.5A) and is excluded from nucleoli (arrows in Figures 3.5A), 
which is consistent with a previous report [118]. With the N-terminal 1-164 deletion, the 
punctate pattern disappeared and the FUS protein was evenly distributed in the entire 
nucleus including nucleoli (Figure 3.5B). The results indicate that the punctate pattern 
inside the nucleus observed under the confocal microscope may be related with FUS 
chromatin binding.  
The role of FUS chromatin binding in transcription regulation and alternative 
splicing  
FUS has been shown to regulate gene transcription [63, 110, 114] and alternative 
splicing [63, 64]. We next tested the relationship between chromatin binding and FUS 
function in gene transcription and alternative splicing using the full-length FUS and the 
truncated FUS 165-526 that is deficient in chromatin binding. We used a manganese 
superoxide dismutase (MnSOD) reporter assay since FUS was shown to activate the 
transcription of MnSOD [110]. The full-length FUS or FUS 165-526 along with a 
reporter plasmid carrying the MnSOD promoter were transfected into HEK cells. 
MnSOD reporter gene activities showed that the full-length FUS increased reporter gene 
activity approximately two folds, as compared to the non-transfected control (p < 0.01; 
Figure 3.6A). In contrast, the truncated FUS 165-526 lost the ability of increasing 
MnSOD reporter gene activity. In addition, we tested the transcription activation of 
another gene histone-lysine N-methyltransferase SMYD3 that was previously reported to 
be regulated by FUS [64]. Similarly, truncated FUS 165-526 failed to activate the 
transcription of the endogenous SMYD3 gene (Figure 3.6B). The protein levels of 
exogenous full-length FUS, FUS 165-526, and endogenous FUS were comparable 
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(Figure 3.6C). Since FUS 165-526 is deficient in chromatin binding, the results suggest 
that chromatin binding is required for FUS function in regulating gene transcription.  
The role of FUS in regulating mRNA splicing was examined using a minigene 
splicing assay [111]. The full-length FUS or FUS 165-526 construct along with the 
minigene plasmids were transfected into HEK cells. Reverse transcription PCR was used 
to detect alternative splicing products. Overexpression of the full-length FUS decreased 
exon inclusion in E1A and insulin receptor transcripts (Figure 3.7A). Overexpression of 
the truncated FUS 165-526 had a similar effect on the splicing of both minigenes as full-
length FUS. Quantitative analysis showed that the ratio of inclusion and exclusion 
transcripts changed in a similar fashion by the overexpression of either full-length FUS or 
truncated FUS 165-526 that is incapable of binding to chromatin (Figure 3.7A), i.e. the 
truncated FUS 165-526 was as effective as the full-length FUS in regulating alternative 
splicing. We also showed that FUS overexpression did not affect the splicing of lamin 
A/C (LMNA Mut) in the minigene assay (Figure 3.7A bottom). This negative control 
supports the specificity of the splicing results. The results suggest that chromatin binding 
is not required for FUS to function in alternative splicing, although it is required for FUS 
regulation of gene transcription. In Figure 3.7B, we showed a similar trend of regulation 
with SMN2 and Tau minigenes. 
The N-terminal QGSY-rich region mediates FUS self-assembly 
We next determined why the N-terminal amino acids 1-164 of FUS are required 
for FUS chromatin binding. The N-terminal QGSY-rich region is so named based on the 
fact that about 80% of the amino acid residues in this region are glutamine, glycine, 
serine, or tyrosine. This region is intrinsically disordered, we thus reasoned that a binding 
partner may cooperatively mediate FUS chromatin binding. To identify binding 
partner(s), we expressed GST-tagged FUS 1-164, FUS 165-526, and full-length FUS in 
HEK cells and did a GST pull-down. Next we used mass spectrometry analysis to 
determine interacting proteins. The criteria for a putative partner are: it should interact 
with FUS 1-164 and full-length FUS, but not with FUS 165-526. No other proteins were 
identified to qualify for the above criteria, with the exception of endogenous FUS (Figure 
3.8). The results suggest that FUS may interact with itself through the QGSY-rich region. 
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We hypothesized that self-oligomerization of FUS through the N-terminal QGSY-
rich region is critical to FUS chromatin binding ability. To test this hypothesis, we 
substituted the QGSY-rich region with a DsRed variant (DsRed2) that can form tetramers 
[119] (Figure 3.9A left). Whereas the GST-tagged FUS 165-526 was not found in the 
chromatin-bound fraction (Figure 3.4B), the DsRed2-tagged FUS 165-526 was found in 
the chromatin-bound fraction (Figure 3.9B). As a control, a monomeric DsRed variant 
(DsRed-M) [120] was tagged to FUS 165-526 (Figure 3.9A right). The monomeric 
DsRed-tagged FUS 165-526 was not detected in the chromatin-bound fraction (Figure 
3.9B). Thus, we conclude that oligomerization of FUS through the N-terminal QGSY 
region (1-164) is essential for FUS chromatin binding. The tetrameric DsRed2 tag also 
restored the punctate distribution and nucleolar exclusion of FUS 165-526 (top of Figure 
3.10, compare to Figure 3.5 A and B) whereas the monomeric DsRed tagged FUS 165-
526 was evenly distributed in the nucleus (bottom of Figure 3.10). As a control, DsRed2 
alone showed an even distribution throughout the cell (middle of Figure 3.10), supporting 
that the punctate distribution of DsRed2-FUS 165-526 is caused by its chromatin binding.  
We next used native gel electrophoresis to examine the self-assembly of 
endogenous FUS in HEK cells. We prepared the soluble and chromatin-bound FUS in a 
similar fashion as in Figure 3.1 and chromatin-bound proteins were released to the 
solution by sonicating the resuspended pellet (Figure 3.11). The soluble and chromatin-
bound fractions were subjected to native gel electrophoresis followed by Western blot 
analysis with the FUS antibody. The chromatin-bound FUS migrated as a much slower 
band as compared to the soluble FUS that is not associated with chromatin (Figure 3.11), 
supporting that the chromatin-bound FUS indeed forms a high order assembly. Combined 
with the results obtained from substituting the N-terminal QGSY-rich region with the 
monomeric or tetrameric DsRed tag, we conclude that FUS binds to chromatin in a self-
assembled complex and the self-assembly is mediated by the N-terminal QGSY-rich 
region. 
RNA is also required for FUS self-assembly  
Because FUS is an RNA binding protein, we tested whether RNA plays a role in 
FUS chromatin binding. RNase A was added to a freshly made HEK cell lysate prior to 
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centrifugation and SDS and Benzonase incubation. The levels of FUS in the chromatin-
bound fraction decreased dramatically with increasing amounts of RNase A (Figure 
3.12). At the highest RNase A concentration (100 µg/ml), no FUS was detected in the 
chromatin-bound fraction, suggesting that FUS chromatin binding is RNA dependent. We 
also tested the RNA dependency of chromatin binding of DsRed2-tagged FUS 165-526 
that lacks the N-terminal QGSY-rich region. Surprisingly, the binding of DsRed2-tagged 
FUS 165-526 to chromatin did not decrease in the presence of increasing amounts of 
RNase A (Figure 3.13). Since DsRed2 oligomerization does not require RNA, the 
difference of RNA dependency between the full-length FUS and the DsRed2-tagged FUS 
165-526 suggest that RNA may be required for the assembly of the full-length FUS. To 
test this, RNase A was added in the sonication lysate containing the chromatin-bound 
FUS. Native gel electrophoresis showed that the slower-migrating FUS band, which is 
the assembled and chromatin-bound FUS, shifted toward the nuclear soluble FUS in the 
presence of RNase A (Figure 3.14). The results consistently support that RNA is required 
for FUS self-assembly.  
Discussion 
FUS is associated with transcriptionally active chromatin and the association is 
impaired by the ALS mutations 
FUS is predominantly localized in the nucleus, however the distribution and 
function of FUS inside the nucleus remain to be fully understood. We found that there are 
two pools of FUS inside the nucleus: nuclear soluble and chromatin bound (Figures 3.1-
3.3). Specifically, the chromatin-bound FUS is associated with transcriptionally active 
chromatin and much less with the condensed inactive chromatin (Figure 3.3A). A 
recently published study showed the co-localization of FUS with the activated form of 
RNA polymerase II in the nucleus [121], supporting our biochemical association of FUS 
with active chromatin. Moreover, the association of FUS with active chromatin was 
significantly reduced by the ALS mutations R521G and R495X (Figure 3.2 and 3.3B). 
The reduced chromatin binding by the ALS mutants suggests that the disease-causing 
mutations may result in a loss of function in the nucleus. 
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Chromatin binding of FUS is required for its function of regulating gene 
transcription, but not for its role in alternative splicing 
The observation that FUS binds to active chromatin is consistent with earlier 
reports that FUS can regulate gene transcription [110, 114]. This study shows that the 
truncated FUS 165-526 lacking the N-terminal QGSY-rich region is incapable of binding 
to chromatin. Moreover, the truncated FUS 165-526 did not activate MnSOD and 
SMYD3 gene transcription (Figures 3.6A and 3.6B), supporting that the chromatin-
binding property of FUS is required for its gene transcription regulation function. This 
significance of FUS chromatin binding in gene transcription regulation is supported by a 
previous report that knock-down of FUS in mouse brain decreased expression of 
hundreds of genes [64]. The requirement of chromatin binding for its gene transcription 
activation, along with the finding that ALS mutations impair chromatin binding, provides 
a mechanism for the previous observation that the ALS mutant FUS lost its transcription 
activation capability [110].  
In contrast to gene transcription, the splicing of E1A and insulin receptor 
minigenes was largely unchanged between the full-length FUS and the truncated FUS 
165-526 (Figure 3.7), suggesting that FUS regulation of alternative splicing does not 
require its chromatin binding property. Combined together, these results suggest that two 
different pools of FUS in the nucleus, i.e. chromatin-bound and nuclear soluble FUS, 
regulate gene transcription and alternative splicing, respectively (Figure 3.15).  
A prion-like domain is also found in another RNA binding protein TDP-43 that is 
also implicated in ALS. Interestingly, the prion-like domain of TDP-43 is required for 
TDP-43 splicing regulation, but not for transcription activation [122]. Our study reveals a 
significant difference between the functional relevance of the prion-like domain of FUS 
and that of TDP-43, suggesting that FUS and TDP-43 may function differently in the 
nucleus. 
The role of the QGSY-rich region in FUS self-assembly and chromatin binding 
The N-terminal domain of FUS (amino acids 1-239) has been predicted to be a 
prion-like domain [96]. Prion was originally coined to describe a pathogenic protein 
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(PrPsc) which can use itself as template to convert native protein (PrP) into a misfolded 
conformation and subsequently form amyloid-like aggregates. The prion-like activity has 
been described in yeast [97] as well as multicellular organisms, involving various 
processes such as antiviral signaling [123, 124] and memory formation [125]. The prion-
like domain in RNA binding proteins is involved in the formation of dynamic and 
reversible structures such as stress granules [126] and processing bodies [127]. In this 
study, we determined that the QGSY-rich region (1-164) within the prion-like domain is 
essential and sufficient for chromatin binding of FUS (Figure 3.4). Using native gel 
electrophoresis and the substitution of the QGSY-rich region with monomeric and 
tetrameric DsRed (Figures 3.9-3.11), we demonstrated that this region is required for 
high order assembly of FUS and the binding of FUS to chromatin. This is a new function 
of the QGSY-rich region identified in this study.  
It remains unclear exactly how the high order assembly of FUS binds to 
chromatin. We propose that FUS chromatin binding is mediated by the interaction 
between FUS and RNA polymerase II. Our finding that FUS is preferentially associated 
with active chromatin (Figure 3.3) supports this notion. In addition, the interaction 
between FUS and the C-terminal domain (CTD) of RNA polymerase II has been 
demonstrated in vitro [63, 100, 128, 129]. In this study, tetrameric DsRed can restore 
chromatin binding of the truncated FUS 165-526, indicating that the QGSY-rich region 
(1-164) is only responsible for self-assembly but not the physical interaction with RNA 
polymerase II. Since the N-terminal domain (1-266) is reported to be responsible for 
interacting with RNA polymerase II [100], the physical interaction is likely mediated by 
the glycine-rich region (165-266).  
RNA dependence of FUS self-assembly and chromatin binding 
This study shows that RNA molecules are also required for FUS self-assembly 
and chromatin binding since RNase A treatment disrupted FUS self-assembly (Figure 
3.14) and reduced FUS chromatin binding to a undetectable level (Figure 3.12). It is 
noted in Figure 3.4 that truncation mutants of FUS lacking the zinc finger domain (FUS 
1-164, 1-284 and 1-370) showed lower abundance in the chromatin-bound fraction as 
compared to those containing the zinc finger domain (FUS 1-494 and full-length FUS). 
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Since the zinc finger domain and the RNA recognition motif (RRM) are both nucleic acid 
binding domains, our interpretation is that the zinc finger domain can contribute to FUS 
RNA binding and subsequently chromatin binding. The results combined together 
support the critical role of RNA dependence of FUS chromatin binding.  
We further propose that RNA molecules initiate FUS self-assembly and 
chromatin binding. This model explains the coexistence of the two pools of FUS 
(assembled/chromatin-bound and soluble) in the nucleus (Figure 3.15). In the presence of 
appropriate RNA molecules, FUS assembles, binds to active chromatin and carries out its 
gene transcription regulation function. In the absence of RNA, FUS remains soluble and 
carries out other functions such as regulating splicing. Indeed, a previous study 
demonstrated that non-coding RNAs recruit FUS to chromatin to regulate gene 
expression [130]. A more recent study showed RNA molecules seeded high-order 
assembly of FUS in vitro [129], supporting the proposed model in Figure 3.15.   
Significance of FUS chromatin binding in ALS 
This study shows that the N-terminal QGSY-rich region is required for self-
assembly of FUS under physiological conditions. This physiological assembly is essential 
for FUS intranuclear distribution and correlated functions such as transcription activation. 
The ALS mutations disrupt this assembly and chromatin binding, which could result in 
several potentially adverse consequences. The ALS mutations R521G and R495X, which 
significantly decreased FUS chromatin binding, were found to impair the gene 
transcription of a critical mitochondrial antioxidant protein MnSOD [110]. FUS 
chromatin binding may also be crucial for DNA damage repair. FUS is among one of the 
early response proteins in DNA damage repair [60, 61]. Deleting the N-terminal amino 
acids 1-285 significantly reduced FUS recruitment to DNA damage sites induced by laser 
micro-irradiation [61]. Deficient binding of FUS to chromatin can result in increased 
DNA damage and genome instability which is especially harmful to the terminally-
differentiated non-dividing neurons. This notion is also supported by a recent study 
showing that the ALS mutation R521C caused DNA damage in a transgenic mouse 
model [91].  
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In summary, FUS self-assembly and binding to chromatin in the nucleus under 
physiological conditions are critical to its proper function. Disrupting FUS assembly and 
chromatin binding can cause perturbations in multiple cellular processes and ultimately 
lead to motor neuron dysfunction and degeneration in ALS.  
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Figure 3.1 A portion of nuclear FUS is chromatin-bound. 
(A) Flowchart of chromatin-bound protein isolation by SDS and benzonase extraction. 
Cell lysates were prepared by passing through a 23-gauge needle and subjected to 1,000 
× g centrifugation for 10 min. Chromatin-bound proteins were released from the pellet by 
incubation with RIPA buffer containing 0.3% SDS and 250 units/mL benzonase. The 
soluble (S) and chromatin-bound (CB) fractions were subjected to SDS/PAGE and 
Western blot with indicated antibodies. (B) HEK cell lysates were separated into 
cytoplasmic (C), membrane (M), nuclear soluble (NS), chromatin-bound (CB), and 
cytoskeletal (Sk) fractions using a Pierce Subcellular Protein Fractionation kit. Each 
fraction was subjected to SDS/PAGE and Western blot with indicated antibodies. 
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Figure 3.1 A portion of nuclear FUS is chromatin-bound
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Figure 3.2 ALS mutations decrease FUS chromatin binding. 
The distribution of GST-tagged wild-type FUS and ALS mutants R521G and R495X was 
examined by the fractionation method as in Figure 3.1B. The ratio of CB and NS was 
quantified and the results from three independent experiments are presented. *P < 0.02. 
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Figure 3.2 ALS mutations decrease FUS chromatin binding	
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Figure 3.3 FUS is bound to active chromatin. 
(A)The flowchart shows the preparation of active and inactive chromatin domains using a 
previously published salt elution protocol [115]. HEK cell nuclei were separated from 
cytoplasm (S1) and washed with separation buffer (W1) before micrococal nuclease 
(MNase) treatment to release nuclear soluble proteins (S2). After second time wash (W2), 
nuclei were extracted with 150 mM NaCl (E1) and 600 mM NaCl (E2) sequentially. The 
remnant pellet was resuspended in 2% SDS loading buffer (P). All fractions (S1, W1, S2, 
W2, E1, E2, and P) were subjected to SDS/PAGE and Western blot with indicated 
antibodies (Upper) or agarose gel electrophoresis and ethidium bromide staining (Lower). 
(B) The association of GFP-tagged wild-type FUS and ALS mutants R521G and R495X 
with active chromatin was examined using the salt elution protocol as in A. The ratio of 
FUS in E1 and S2 was quantified and the results from three independent experiments are 
presented. *P < 0.05. The antibodies used in Western blot were: SOD1, a primarily 
cytoplasmic protein; transcription factor Sp1, a nuclear soluble protein; histone H3, a 
chromatin-bound protein; and histone H1, a protein associated with inactive chromatin. 
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Figure 3.3 FUS is bound to active chromatin 
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Figure 3.4 QGSY-rich region is responsible for FUS chromatin binding. 
(A) Diagram of GST-tagged full-length (FL) FUS and truncated mutants used in the 
study. (B) The QGSY-rich region is required for FUS chromatin binding. HEK cells 
expressing FUS FL and truncated mutants were subjected to the chromatin-bound protein 
separation protocol by SDS and benzonase extraction as shown in Figure 3.1A. The 
chromatin-bound and soluble fractions were subjected to SDS/PAGE and Western blot 
with indicated antibodies.  
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Figure 3.4 QGSY-rich region is responsible for FUS chromatin binding 
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Figure 3.5 QGSY-rich region is required for FUS intranuclear distribution. 
(A) The intranuclear distribution of EGFP-FUS. Green, EGFP-tagged FUS; red, Nop56; 
blue, DAPI staining of DNA; arrows, nucleoli. Confocal microscopic analysis showed a 
granular punctate distribution of FUS inside the nucleus. Moreover, FUS was not 
colocalized with the nucleolar marker Nop56, suggesting that FUS is excluded from 
nucleoli under physiological conditions. The confocal images were acquired using a 
Nikon A1 confocal microscope as described in Chapter 2. (B) QGSY-rich region deletion 
abolished FUS characteristic distribution pattern. Green, EGFP-tagged FUS; blue, DAPI 
staining of DNA; arrows, nucleoli. 
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Figure 3.5 QGSY-rich region is required for FUS intranuclear distribution 
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Figure 3.6 Chromatin binding is required for FUS transcription regulation. 
(A) The transcription activation by FUS was monitored by a dual luciferase reporter 
assay as described in Chapter 2. Diagram shows Firefly luciferase gene is driven by the 
MnSOD promoter and Renilla luciferase gene is driven by the HSV TK promoter as a 
control. Bar graph shows the ratio of Firefly and Renilla luciferase activities in the 
presence of full-length FUS or FUS 165–526 lacking the QGSYrich region. The results 
from three independent experiments are presented. NT, only reporter plasmid transfected. 
*P < 0.01. (B) The transcription activation of endogenous SMYD3 gene by FUS as 
measured by real-time PCR. The results from three independent experiments are 
presented. *P < 0.05. (C) Western blot of lysates from HEK cells transfected with 0.5 μg 
pEGFP-C3-FUS as described in Chapter 2. Cell lysates were collected 48 h after 
transfection and the membrane was blotted with FUS antibody. * indicates endogenous 
FUS. 
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Figure 3.6 Chromatin binding is required for FUS transcription regulation 
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Figure 3.7 Chromatin binding is not required for FUS splicing regulation. 
(A) The mRNA splicing regulation by FUS was monitored by minigene splicing assay. 
(Left) The diagram of alternative splicing of the E1A, insulin receptor, and LMNA Mut 
minigenes. Dash lines indicate exon inclusion, whereas solid lines indicate exon 
exclusion in splicing products. (Middle) Images of the ethidium bromide-stained gels 
show minigene transcript variants in HEK cells expressing full-length FUS or FUS 165– 
526 lacking the QGSY-rich region. The major exon inclusion and exon exclusion 
transcripts are indicated, respectively. (Right) The ratio of exon inclusion and exon 
exclusion transcripts was quantified and results from three independent experiments are 
presented in the bar graph. *P < 0.01. N.S., no significant difference. (B) SMN2 and Tau 
minigenes splicing are also regulated by FUS. Shown are the representative results from 
two independent experiments. 
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Figure 3.7 Chromatin binding is not required for FUS splicing regulation 
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Figure 3.8 Self-interaction of FUS through the QGSY-rich region 
Identification of the endogenous FUS in GST-FUS pull-down samples. GST-tagged FUS 
1-164, FUS 165-526, and full-length FUS were expressed in HEK cells. GST pull-down 
was performed and the pull-down samples were subjected to shot-gun proteomics 
analysis using LC-MS/MS as described in Chapter 2. The endogenous FUS was 
identified as an interacting protein with GST-FUS 1-164 and GST-FUS full length, but 
not with GST-FUS 165-526. Four and three unique peptides were identified in the GST 
pull-down samples of GST-FUS 1-164 and GST-FUS full length, respectively. In the 
GST-FUS 1-164 pull-down sample, all four peptides are from FUS sequences beyond the 
N-terminal 1-164 residues, thus the endogenous FUS must be an interacting protein with 
truncated FUS 1-164. The mass spectrometric experiments were performed by Dr. Jing 
Chen in our lab. 
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Figure 3.8 Self-interaction of FUS through the QGSY-rich region 
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Figure 3.9 Oligomerization restored FUS 165-526 chromatin binding. 
(A) Diagram of FUS 165-526 tagged by tetrameric DsRed2 or monomeric DsRed-
Monomer. (B) Tetrameric DsRed2 restored the binding of FUS 165-526 to chromatin, 
whereas monomeric DsRed-tagged FUS 165-526 was not detected in the chromatin-
bound fraction. HEK cells were transfected with DsRed2-FUS 165-526 or DsRed-
Monomer-FUS 165-526 or the corresponding DsRed control. The chromatin-bound 
proteins were prepared by SDS and benzonase extraction as shown in Figure 3.1A. The 
chromatin-bound and soluble fractions were subjected to SDS/PAGE followed by 
Western blot. 
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Figure 3.9 Oligomerization restored FUS 165-526 chromatin binding 
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Figure 3.10 Oligomerization restored FUS 165-526 characteristic distribution. 
DsRed2-FUS 165-526 showed granular distribution and nucleolar exclusion inside the 
nucleus, similar to that of the full-length FUS. The monomeric DsRed-tagged FUS 165-
526 was evenly distributed in the nucleus. Cells were fixed 24 h after transfection and 
subjected to confocal microscopic analysis. Red, DsRed and DsRed-tagged FUS; blue, 
DAPI staining of DNA; arrows, nucleoli. 
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Figure 3.10 Oligomerization restored FUS 165-526 characteristic distribution	
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Figure 3.11 Endogenous FUS self-assembly 
The chromatin-bound (CB) and soluble (S) fractions were prepared similarly as in Figure 
3.1A, except the cells were lysed in detergent-free buffer instead of RIPA buffer and the 
pellet was resuspended by sonication instead of SDS and benzonase treatment. CB and S 
fractions were subjected to native gel electrophoresis and Western blot as described in 
Chapter 2. The slow mobility of FUS suggests a high order assembly of FUS in the CB 
fraction. 
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Figure 3.11 Endogenous FUS self-assembly 
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Figure 3.12 FUS chromatin binding is RNA dependent. 
HEK cell lysates were incubated with indicated amounts of RNase A for 20 min on ice 
before separation of the chromatin-bound and soluble fractions using the protocol as in 
Figure 3.1A. The amount of chromatin-bound FUS in the presence of RNase A was 
examined by Western blot. 
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Figure 3.12 FUS chromatin binding is RNA dependent 
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Figure 3.13 DsRed2-FUS 165-526 chromatin binding is independent of RNA. 
HEK cells were transfected with DsRed2-FUS 165-526 and harvested 48 h after 
transfection. Cell lysates were incubated with indicated amounts of RNase A for 20 min 
on ice and separated to the chromatin-bound and soluble fractions. The amount of 
chromatin-bound DsRed2-FUS 165-526 in the presence of RNase A was examined by 
Western blot.  
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Figure 3.13 DsRed2-FUS 165-526 chromatin binding is independent of RNA 
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Figure 3.14 RNA is required for FUS self-assembly. 
The chromatin-bound fraction as in Figure 3.11 was incubated with indicated amounts of 
RNase A and subjected to native gel electrophoresis. The soluble fraction was included as 
a control. 
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Figure 3.14 RNA is required for FUS self-assembly 
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Figure 3.15 Proposed model of FUS self-assembly and chromatin binding.  
Wild-type FUS forms high order assemblies and binds to active chromatin where FUS 
regulates gene transcription. FUS regulation of mRNA splicing does not require self-
assembly or chromatin binding, thus is mediated by the pool of soluble FUS. 
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Figure 3.15 Proposed model for FUS self-assembly and chromatin binding 
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Chapter 4: Subcellular Localization and RNAs Determine FUS Architecture in 
Different Cellular Compartments 
Introduction  
Fused in sarcoma (FUS) is a DNA/RNA binding protein. Mutations in FUS cause 
a subset of familial amyotrophic lateral sclerosis (ALS) [1, 2]. ALS is a progressive 
neurodegenerative disease characterized by the loss of motor neurons [131].The ALS 
mutations result in the mislocalization of FUS from the nucleus to the cytoplasm and the 
formation of FUS-containing inclusions in the cytoplasm [1, 2]. It is unknown how the 
mislocalization of mutant FUS causes motor neuron dysfunction and degeneration. 
Cytoplasmic FUS inclusions are immune-positive of stress granule markers [55, 104], a 
temporary cellular structure important for cell survival under a variety of stresses [57]. 
The endogenous FUS has also been reported to participate in stress granule formation 
under various stresses [132, 133]. Mutant FUS has been shown to alter stress response 
dynamics, which is hypothesized to cause motor neuron degeneration [134-137]. While 
proteinaceous inclusions involved in neurodegenerative diseases are often composed of 
amyloidal-aggregated misfolded proteins, FUS inclusions are structurally different [86, 
87]. Specifically, FUS inclusions in the brain of frontal temporal dementia (FTD) patients 
were negative of thioflavin-S staining that specially stains cross-β-sheet structures in 
amyloidal aggregates [87]. In addition, SDS-resistant oligomers were not detected in cells 
expressing various FUS mutants [86]. The architecture of FUS protein in the cytoplasmic 
inclusions remains to be determined.  
We previously reported that a sub-population of nuclear FUS is associated with 
active chromatin and participates in gene transcription regulation [110, 114, 138]. The 
ALS mutations reduce FUS chromatin binding, disrupting FUS function in regulating 
gene transcription. We found that the chromatin-bound FUS was oligomerized and 
showed a granular pattern inside the nucleus. FUS oligomerization is mediated by the N-
terminal QGSY-rich region (glutamine, glycine, serine, and tyrosine-rich region) and 
requires RNA binding [138]. The QGSY-rich region is part of a predicted prion-like 
domain [96] that is required for FUS aggregation in vitro [98]. Therefore we examined 
whether the QGSY-rich-region mediated oligomerization is also the structural basis of 
63 
 
FUS cytoplasmic inclusions. The results will help us understand the nature of FUS 
cytoplamic inclusions. In addition, better understanding of the architectures of FUS 
proteins in the nuclear and cytoplasmic compartments will help determine whether 
redirecting cytoplasmic FUS mutants into the nucleus would be a potential therapeutic 
intervention for ALS as proposed in recent studies [107, 108, 139-141]. Moreover, the 
requirement of RNA binding in FUS binding to chromatin raised the question whether 
RNAs directly mediate FUS protein organization in the nuclear granules and cytoplasmic 
inclusions.  
In this study, we revealed that, in contrast to nuclear granules of FUS, the 
formation of FUS cytoplasmic inclusions does not require the QGSY-rich region 
mediated oligomerization. By examining wild-type and mutant FUS proteins in different 
cellular compartments, we demonstrated that the subcellular localization plays an 
important role in determining the FUS protein architecture. We also discovered that 
chromatin-associated RNAs are critical to initiate the oligomerization of nuclear FUS. 
Moreover, the RNA binding ability was also required for FUS cytoplasmic inclusion 
formation. These results collectively suggest that subcellular localization and local RNA 
species are the determining factors for FUS distinct architectures and distribution patterns 
in different cellular compartments.     
Results 
FUS proteins are organized differently in nuclear granules and cytoplasmic 
inclusions.  
We have recently reported that the QGSY-rich region mediated FUS 
oligomerization is essential for the formation of nuclear granules of FUS [138]. When the 
QGSY-rich region (amino acids 1-164) was deleted, the granular distribution pattern 
disappeared and FUS molecules diffused in the entire nucleus (Figure 4.1A). We 
examined whether the QGSY-rich region mediated oligomerization was also the 
structural basis of cytoplasmic inclusions of mutant FUS. FUS R495X (arginine 495 to 
stop codon, a deletion mutant causing aggressive ALS [142, 143]) formed cytoplasmic 
inclusions that were co-localized with the stress granule maker G3BP1 (Figure 4.1B). We 
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deleted the QGSY-rich region from FUS R495X and found that the truncation protein 
still formed cytoplasmic inclusions co-localized with G3BP1 (Figure 4.1B). The results 
suggest that the QGSY-rich region is not required for the inclusion formation of ALS 
mutant FUS in the cytoplasm. The above results provide the initial evidence that FUS 
proteins in the nuclear granules and cytoplasmic inclusions are organized differently. 
Subcellular compartment determines distinct local distribution patterns of FUS. 
The above results also raised an interesting question: what causes different local 
distribution patterns of FUS protein in different cellular compartments? Two factors can 
potentially contribute to it: subcellular compartment (nucleus versus cytoplasm) and 
protein mutation (wild-type versus ALS mutations). We rationalized that simultaneous 
examination of the local distribution pattern of nuclear and cytoplasmic subpopulations 
of mutant FUS protein can help delineating which factor plays a more important role. We 
took advantage of ALS point mutations (e.g. R521G) that cause partial retention of FUS 
protein in the cytoplasm while maintaining a significant portion in the nucleus. FUS 
R521G exhibited granular distribution and was excluded from nucleoli (arrows in Figure 
4.2A), which is very similar to wild-type FUS in the nucleus (compare to Figure 4.1A). 
This pattern was also observed in the fibroblast cells derived from familial ALS patient 
carrying the R521G mutant FUS (Figure 4.2B). The cytoplasmic retained FUS R521G 
mutant formed inclusions (Figure 4.2A, left image, arrow heads). We deleted the QGSY-
rich region of FUS R521G and examined how it changed the distribution of FUS protein 
in the nucleus and cytoplasm. The granular pattern of FUS R521G in the nucleus 
disappeared and FUS R521G was evenly distributed in the entire nucleus after the 
QGSY-rich region was deleted (Figure 4.2A, right). The changes of FUS R521G in the 
nucleus were similar to the effect of QGSY-rich region deletion on wild-type FUS 
(Figure 4.1A, bottom row). In contrast, cytoplasmic inclusions of FUS R521G were still 
observed upon the deletion of the QGSY-rich region (Figure 4.2A, right, arrow heads), 
which is similar to the effect of QGSY-rich region deletion on FUS R495X (Figure 4.1B, 
bottom row). These observations suggest that the subcellular compartment (i.e. nuclear or 
cytoplasmic) plays an important role in determining the local distribution pattern of FUS.  
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To further test this notion, we generated two chimeric proteins: FUS R495X fused 
with a nuclear localization sequence (NLS) from hnRNPD and wild-type FUS tagged 
with a typical nuclear export sequence (NES) (Figure 4.3A). The chimeric protein R495X 
+ hnRNPD NLS was largely localized inside the nucleus and showed a punctate pattern 
with nucleolar exclusion (Figure 4.3B), resembling wild-type FUS (compare to Figure 
4.1A). Tagging the NES to wild-type FUS brought the protein outside the nucleus and the 
chimeric protein formed inclusions in the cytoplasm (Figure 4.3C), which is similar to 
R495X (compare to Figure 4.1B). These results solidify the notion that the subcellular 
compartment is the critical factor determining the local distribution pattern of FUS.  
The ALS mutant FUS protein in the nucleus responds to transcription inhibition in 
a similar fashion to wild-type FUS.  
The above results suggest that ALS mutations have little effect on the local 
distribution pattern of the FUS protein localized in the nucleus. To further test this notion, 
we treated cells with transcription inhibitor 5,6-dichloro-1-β-D-ribofuranosyl-1H-
benzimidazole (DRB) and examined how wild-type and mutant FUS proteins responded 
to this stress. The wild-type FUS protein accumulated into areas close to nucleoli upon 
DRB treatment (Figure 4.4A), consistent with previous reports [118, 144]. Similarly, 
FUS R521G and FUS R495X (Figure 4.4B) mutant proteins also accumulated next to 
nucleoli upon DRB treatment. The result again suggests that the nuclear localized mutant 
FUS responds to transcription inhibition similarly to wild-type FUS.  
Chromatin-associated mutant FUS oligomerizes similarly to wild-type FUS.  
Our recently published results suggest that there are two pools of FUS inside the 
nucleus (chromatin-bound and nuclear soluble) and the granular distribution is attributed 
to the chromatin-bound FUS [138]. In this study, we used two biochemical approaches, 
native gel electrophoresis and chemical crosslinking, to examine the nuclear granules and 
the cytoplasmic inclusions observed in Figure 1. The chromatin-bound (CB) and non-
chromatin-bound (NCB) fractions were prepared from lysates of cells expressing wild-
type, R521G, or R495X FUS as previously described [138] (Figure 4.5A). The 
chromatin-bound FUS represents the portion of FUS producing nuclear granules and the 
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non-chromatin-bound FUS includes the cytoplasmic FUS that can form inclusions. The 
chromatin-bound wild-type FUS migrated slower than the non-chromatin-bound wild-
type FUS (Figure 4.5B), which we previously interpreted that the chromatin-bound FUS 
was oligomeric whereas the non-chromatin-bound was largely monomeric [138]. 
Interestingly, R521G and R495X mutants in both chromatin-bound and non-chromatin-
bound fractions migrated similarly to wild-type FUS in the corresponding fraction 
(Figure 4.5B). The results supported that the mutant FUS proteins behaved similarly to 
wild-type FUS, i.e. mutant FUS also existed as oligomeric form when bound to 
chromatin and as monomeric when in cytoplasm. Although mutant FUS showed reduced 
ability of binding to chromatin [138], the chromatin-bound mutant FUS protein formed 
oligomers as wild-type FUS. The lack of oligomeric mutant FUS in the cytoplasmic 
fraction suggest that the cytoplasmic FUS protein does not need to oligomerize in the 
process of forming inclusions, which is consistent with the earlier results that the QGSY-
rich region is not required for cytoplasmic inclusion formation (Figure 4.1B bottom and 
4.2A, right).  
We performed chemical crosslinking to further examine the oligomeric status of 
FUS proteins. The chromatin-bound wild-type and mutant FUS proteins all formed 
oligomeric species as evidenced by the crosslinked signals (Figure 4.5C). In contrast, no 
crosslinked species were detected for either wild-type or mutant FUS proteins in the non-
chromatin-bound fraction. The above results consistently support that, regardless wild-
type of ALS mutants, the chromatin-bound FUS protein oligomerizes whereas the 
cytoplasmic FUS protein does not.  
Chromatin content initiates oligomerization of wild-type and mutant FUS.  
We next examined what triggers FUS oligomerization. Since the non-chromatin-
bound FUS did not oligomerize no matter how long it was incubated in the cell lysate 
deprived of chromatin content (data not shown), we hypothesized that certain constituents 
in the chromatin-bound fraction initiated FUS oligomerization. We incubated the 
chromatin-bound fraction with the non-chromatin-bound fraction and analyzed them with 
native gel electrophoresis. With increasing amounts of chromatin content in the mixture, 
the wild-type FUS protein shifted from the monomeric position towards the oligomeric 
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position (Figure 4.6A). The result demonstrated that the chromatin content was able to 
initiate oligomerization of non-chromatin-bound FUS. Interestingly, a single band was 
observed in each sample with a position between the monomeric and oligomeric bands 
(Figure 4.6A), suggesting that FUS protein reached a new equilibrium during incubation. 
Similarly, the chromatin content initiated oligomerization of mutant FUS in the non-
chromatin-bound fraction as well (Figure 4.6B). 
Chromatin-associated RNAs are responsible for initiating FUS oligomerization. 
The chromatin fraction contains DNAs, RNAs and proteins, thus we asked what 
triggers FUS oligomerization. Since FUS can bind nucleic acids, we specifically tested 
whether DNA or RNA triggered FUS oligomerization. We incubated RNase-free DNase 
or RNase A along with the chromatin-bound and non-chromatin-bound fractions. The 
RNase treatment abolished mutant FUS oligomerization whereas the DNase treatment 
had no effect on mutant FUS oligomerization (Figure 4.7A). The RNase treatment did not 
change DNA content in the chromatin-bound fraction whereas the DNase treatment 
digested DNAs (Figure 4.7B). The result suggests that RNA molecules associated with 
chromatin are responsible for initiating FUS oligomerization. To confirm this notion, we 
extracted nuclear RNAs with Trizol reagent and incubated them with chromatin-deprived 
cell extract. The Trizol-extracted nuclear RNAs indeed triggered mutant FUS 
oligomerization in a dose-dependent manner (Figure 4.7C). As a control, RNAs extracted 
from the cytoplasmic fraction induced little oligomerization of FUS. The results support 
the notion that the nuclear RNAs associated with chromatin are responsible for initiating 
oligomerization of FUS protein.  
RNA binding is also required for cytoplasmic FUS inclusions.  
We next examined whether RNAs are also involved in inclusion formation of 
cytoplasmic FUS. The RNA recognition motif (RRM) binds to RNA with low affinity 
[101] and the flanking RGG1, RGG2, Zinc-finger (ZnF) and RGG3 motif can potentially 
enhance the RNA binding. We thus generated a series of FUS truncation mutants with 
different RNA binding motifs (Figure 4.8A). R495X mutant FUS formed large inclusions 
in most cells (Figure 4.8B, lower right panel). However, after deleting RGG2/ZnF/RGG3 
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domains, the truncated protein was evenly distributed in the cytoplasm with no inclusions 
(Figure 4.8B, upper left panel). The ΔZnF/RGG3 truncation containing both RRM and 
RGG2 domains formed cytoplasmic inclusions but the proportion of inclusion-containing 
cells is significantly lower than R495X (Figure 4.8B, upper right panel; Figure 4.8C). 
The ΔRGG3 truncation containing RRM, RGG2 and ZnF domains formed inclusions in 
more cells than ΔZnF/RGG3 (Figure 4.8B, lower left panel; Figure 4.8C). The 
quantitative results of the percentage of cells containing cytoplasmic inclusions are 
shown in Figure 4.8C.  
We also examined the RNA binding abilities of the relevant domains using a gel-
shift titration assay. Under the conditions tested, the RRM domain alone did not bind to 
the RNA probe, which is consistent with our previous publication that the binding affinity 
between the RRM domain and RNA was weak (Kd in hundreds µM range) [101]. With 
addition of RGG2, ZnF and RGG3 domains, the binding affinity between the truncated 
FUS and the RNA probe significantly increased as evidenced by the shift of the FUS 
protein band by the RNA probe (Figure 4.8D). The correlation between the stronger RNA 
binding affinity and the increased formation of cytoplasmic FUS inclusions suggests that 
RNA binding is also required for cytoplasmic FUS inclusion formation. 
Discussion  
The architecture of the FUS protein is different in nuclear granules and cytoplasmic 
inclusions.  
Since the cytoplasmic inclusions of mutant FUS are a hallmark of familial ALS 
caused by the FUS mutations, it is critical to understand the structural basis of such 
inclusions. No cross-β-sheet structure, which is typical in amyloidal aggregates, was 
identified in FUS inclusions [86, 87]. The purified FUS protein formed fibrils in vitro and 
the N-terminal prion-like domain (amino acids 1-266) was required for the fibril 
formation [98]. Another study also demonstrated that the FUS N-terminal domain itself 
(amino acids 2-214) formed hydrogel at high concentrations in vitro [95]. We also found 
that the N-terminal QGSY-rich region (amino acids 1-164) was required to form 
functional oligomers in the nucleus, which can be demonstrated by a granular pattern 
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under confocal microscope and a slower motility in native gel electrophoresis [138]. In 
this study, we started testing whether FUS cytoplasmic inclusions are mediated by the N-
terminal domain of FUS.   
We first deleted the QGSY-rich region from R495X mutant FUS and examined its 
distribution under confocal microscope. To our surprise, deletion of the QGSY-rich 
region did not change cytoplasmic inclusions of R495X (Figure 4.1B), suggesting that the 
N-terminal domain is not required for FUS cytoplasmic inclusion formation. This finding 
is in contrast to the observation that FUS nuclear granules disappeared after the deletion 
of the QGSY-rich region (Figure 4.1A). Similar observations were found in cells 
expressing R521G point mutant FUS that was present in both the nucleus and cytoplasm 
(Figure 4.2A). Moreover, native gel electrophoresis (Figure 4.5B) and crosslinking 
(Figure 4.5C) results provided additional evidence that the FUS protein in cytoplasmic 
inclusions mostly existed as the monomeric form. This is in contrast to mutant SOD1 
inclusions where oligomeric SOD1 was readily found [145, 146]. Our results suggest that 
the cytoplasmic FUS inclusions are not disordered-region-mediated fibrillar aggregates 
(Figure 4.9). It is conceivable that FUS inclusions can be amorphous aggregates that can 
either become amyloidal aggregation through a common intermediate [147] or be 
disaggregated by heat shock proteins [148].  
Subcellular compartment determines FUS local distribution pattern and behavior.  
We asked the question whether subcellular compartment or ALS mutation is more 
important to determine FUS protein architecture and local distribution pattern. By forcing 
mutant FUS into the nucleus (Figure 4.3B) and wild-type FUS out of the nucleus (Figure 
4.3C), we found that swapping subcellular compartments completely changed the local 
distribution patterns of FUS protein, regardless wild-type or mutant. The results suggest 
that the subcellular localization plays a critical determining the architecture and 
distribution of FUS in different cell compartments. The ALS-causing mutations clearly 
change the subcellular localization of FUS, but mutations appear to have less influence 
on the local distribution pattern of FUS protein inside the specific compartment. An 
additional implication is that the ALS mutations within the C-terminal NLS have no 
significant impact on the overall conformation of FUS.  
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Moreover, we demonstrated that mutant FUS protein localized in the nucleus 
behaves similarly to the wild-type FUS protein. Specifically, the nucleus-localized 
mutant FUS protein formed granules (Figure 4.2 and 4.3), oligomerized (Figure 4.5) and 
responded to transcription inhibition (Figure 4.4) in a similar fashion to the wild-type 
FUS. The results support the critical significance to restore the nuclear localization of 
mutant FUS that accumulates in cytoplasm aberrantly. Several studies have aimed to 
redirect mutant FUS into the nucleus as a potential therapeutic intervention [107, 108, 
139-141] and this intervention showed beneficial effects in model organisms [108, 139, 
141]. Additional work is needed to test whether this approach can be an effective therapy 
in mammalian models.  
Local RNAs are critical for FUS protein architecture.  
 We demonstrated that chromatin-associated RNAs initiated FUS oligomerization 
(Figures 4.6 and 4.7), which is essential to FUS chromatin binding and the appearance of 
granular distribution in the nucleus. However, we do not know the identities of RNAs 
that trigger FUS oligomerization. A previous study using a chimeric protein of the N-
terminal prion-like domain of FUS and a DNA binding domain of a transcription factor 
FLI showed that microsatellite DNA fragments with repetitive sequence significantly 
enhanced the oligomerization of the prion-like domain of FUS [100]. It is conceivable 
that the proximal binding of multiple FUS chimeric proteins increased the local 
concentration of N-terminal FUS and triggered its oligomerization. This observation 
suggests that nascently transcribed non-coding RNAs, which are still attached on 
chromatin, from microsatellite sites may trigger the oligomerization of full-length FUS in 
the nucleus. Indeed, chromatin-associated non-coding RNA was reported to recruit FUS 
to chromatin to regulate gene transcription [130]. A separate genome-wide study 
identified a substantial portion of FUS binding RNAs as long non-coding RNAs [64]. 
However the specific nuclear RNAs initiating oligomerization of FUS in the nucleus 
remain to be experimentally determined. 
 Interestingly, we also found that the formation of FUS inclusions in the cytoplasm 
also required RNA binding capability (Figure 4.8). FUS has been reported to play a role 
in the formation of stress granules [55, 104, 132, 133], a dynamic cytoplasmic structure 
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containing proteins and messenger RNAs when translation halts in response to a variety 
of stresses. Different from the dynamic stress granules that are normally temporary under 
stresses, the cytoplasmic inclusions of FUS were observed persistently in this study. 
Thus, the RNAs sequestered in the persistent inclusions could result in a loss of function 
of the RNAs and the corresponding proteins. Knowing their identities can help us 
determine what cellular processes might be impaired by mutant FUS.  
Furthermore, we speculate that the RNAs required for nuclear FUS 
oligomerization and cytoplasmic FUS inclusions are likely two separate cohorts, although 
a partial overlap of these two pools is conceivable. In summary, the subcellular 
localization and the local pool of RNAs play a critical role in determining the special 
architecture of FUS protein (Figure 4.9). Such protein architecture may be crucial in 
distinguishing RNA binding protein pathogenic mechanism from non-RNA-binding 
protein misfolding/aggregation mechanism in ALS. Moreover, the findings from this 
study support the feasibility of restoring the nuclear localization of mutant FUS as a 
potential therapeutic strategy of ALS. 
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Figure 4.1 FUS proteins are organized differently in nuclear granules and 
cytoplasmic inclusions.  
(A) Full-length wild-type FUS was expressed in HEK cells and formed nuclear granules 
and was excluded from nucleoli in the nucleus (the top row). These two features were lost 
in the truncated FUS ΔQGSY that lacks the QGSY-rich region (the bottom row). Nop56 
(red) is a marker for nucleoli. (B) The R495X mutant FUS formed cytoplasmic inclusions 
that are co-localized with the stress granule marker G3BP1 (the top row). Deleting the 
QGSY-rich region from R495X did not change the formation of G3BP1-positive 
cytoplasmic inclusions (the bottom row). All images were taken with a Nikon A1 
confocal microscope. Green: EGFP-tagged wild-type or mutant FUS. Blue: DAPI 
staining of DNA. 
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Figure 4.1 FUS proteins are organized differently in nuclear granules and 
cytoplasmic inclusions 
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Figure 4.2 Nucleus-localization plays important role in determining FUS granular 
distribution.  
(A) R521G mutant FUS was expressed in HEK cells and formed both nuclear granules 
excluded from nucleoli and cytoplasmic inclusions (the left panel). Arrows: nucleoli. 
Arrow heads: cytoplasmic EGFP-FUS R521G inclusions. Deleting the QGSY-rich region 
did not change the cytoplasmic inclusions, but changed the distribution of R521G FUS 
inside the nucleus (the right panel). The granular pattern disappeared and FUS was 
evenly distributed in the entire nucleus. Green: EGFP-FUS R521G. Blue: DAPI staining 
of DNA. (B). Immunostaining of FUS in fibroblast cells derived from a familial ALS 
patient carrying the R521G FUS mutation. The nuclear population of FUS showed 
granular pattern and was excluded from nucleoli. Green: FUS; red: Nop56; and blue: 
DAPI staining of DNA. All images were taken with a Nikon A1 confocal microscope. 
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Figure 4.3 Subcellular localization plays fundamental role in determining FUS 
different organization.  
(A). Domain structure of FUS and various FUS constructs used in this study. (B) FUS 
R495X formed inclusions in the cytoplasm (the left panel). Tagging FUS R495X with a 
nuclear localization sequence (NLS) targeted the chimeric protein in the nucleus (the 
right panel). The granular pattern of the chimeric protein in the nucleus was similar to 
wild-type FUS. (C) Tagging the wild-type FUS (the left panel) with a nuclear export 
sequence (NES) caused the cytoplasmic localization of the chimeric protein (the right 
panel). The wild-type FUS targeted to the cytoplasm also formed inclusions in a similar 
fashion to mutant FUS. All images were taken with a Nikon A1 confocal microscope. 
Green: EGFP-tagged wild-type or mutant FUS. Blue: DAPI staining of DNA. 
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Figure 4.3 Subcellular localization plays fundamental role in determining FUS 
different organization 
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Figure 4.4 FUS mutants responded to transcription inhibition similarly as wild-type 
FUS.  
(A) Wild-type FUS accumulated in areas close to nucleoli in the presence of transcription 
inhibitor DRB. Cells expressing FUS were treated with 25 μM DRB for 2 h followed by 
formaldehyde fixation and Nop56 immunostaining. (B) FUS mutants R521G and R495X 
also accumulated in the peri-nucleolus areas in the presence of DRB. Cells expressing 
R521G or R495X FUS were treated with 25 μM DRB for 2 h before formaldehyde 
fixation. All images were taken with a Nikon A1 confocal microscope.  Green: EGFP-
tagged FUS. Red: Nop56. Blue: DAPI staining of DNA.    
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Figure 4.4 FUS mutants responded to transcription inhibition similarly as wild-type 
FUS 
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Figure 4.5 FUS mutants oligomerized similarly as wild-type FUS.  
(A) Flow chart of preparing chromatin-bound and non-chromatin-bound samples. (B) 
R521G and R495X mutant FUS proteins migrated similarly as wild-type FUS in native 
gel in both chromatin-bound (CB) and non-chromatin-bound (NCB) fractions. In the CB 
fraction, both mutant and wild-type FUS migrated as oligomers. In the NCB fraction, 
both mutant and wild-type FUS migrated as monomers. (C) The CB and NCB samples 
were subjected to crosslinking by 1% formaldehyde at room temperature for 10 min. 
SDS/PAGE analysis showed crosslinked oligomers for both wild-type and mutant FUS in 
the CB fraction.   
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Figure 4.5 FUS mutants oligomerized similarly as wild-type FUS 
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Figure 4.6 The chromatin-bound fraction induced oligomerization of FUS in the 
non-chromatin-bound fraction.  
(A) Incubation of the CB and NCB fractions induced oligomerization of wild-type FUS 
in the NCB fraction. Different amounts of chromatin-bound samples were incubated with 
the NCB samples on ice for 20 min. The mixtures were subjected to native gel 
electrophoresis followed by Western blot with a FUS antibody. The individual CB and 
NCB fractions were shown as control. The slower mobility of FUS suggested a high 
order assembly of FUS. (B) The R495X mutant FUS also oligomerized when incubated 
with the CB fraction.    
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Figure 4.6 The chromatin-bound fraction induced oligomerization of FUS in the 
non-chromatin-bound fraction 
 
 
 
   
84 
 
Figure 4.7 Nuclear RNAs triggered FUS oligomerization.  
(A) Addition of RNase A in the mixture of CB and NCB fractions inhibited the 
oligomerization of FUS. In contrast, DNase did not have any effect on FUS 
oligomerization. 50 U/ml RNase-free DNase or 1 ng/ml RNase A was added into mixture 
of the NCB sample isolated from cells expressing R495X FUS and the CB fraction (1:1 
ratio). After 1 hr incubation at room temperature, the samples were subjected to native 
gel electrophoresis and Western blot with GFP antibody. (B) Agarose gel electrophoresis 
followed by ethidium bromide staining was performed to examine the nucleic acid 
contents in the mixtures from (A). DNA (500-10,000 bp smear) and RNA (visible in the 
top part of NT lane, > 10,000 bp, and in the full DNase lane) was evidently degraded in 
the presence of DNase and RNase, respectively. (C) The NCB fraction (50 μl) isolated 
from cells expressing R495X FUS was incubated with 2 or 20 μg of nuclear RNAs 
extracted with the Trizol reagent. After incubation at 4 °C overnight, the samples were 
subjected to native gel electrophoresis and Western blot. 
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Figure 4.7 Nuclear RNAs triggered FUS oligomerization 
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Figure 4.8 RNA binding was also required for the formation of FUS cytoplasmic 
inclusions.  
(A) Diagram of GST tagged R495X FUS and a series of truncations lacking RNA 
binding motifs. QGSY, the QGSY-rich region; G, the glycine-rich region; RRM, the 
RNA recognition motif; RGG, arginine-glycine-glycine repeat regions; and ZnF, the zinc 
finger motif. (B) Inclusion formation of the GST tagged R495X FUS and the RNA 
binding motif truncation mutants in HEK cells. GST-FUS mutants were immunostained 
with a GST antibody and the images were acquired with a Nikon A1 confocal 
microscope. The insets are magnified areas indicated by yellow squares. Green: GST-
FUS. Blue: DAPI staining of DNA. (C) The percentages of inclusion-containing cells 
with different FUS R495X truncation mutants. More than a hundred cells in three random 
view fields were counted for each different truncation mutant. Data shown represent 
mean +/- SD and p values were calculated using Student t-test. (D) In vitro RNA binding 
of FUS truncation mutants with different RNA binding motifs. Indicated concentrations 
of purified FUS truncation proteins were incubated with 5’-Cy3-labeled RNA probe and 
the samples were subjected to polyacrylamide gel electrophoresis (see details in Chapter 
2). The images were acquired with a ProteinSimple gel imaging system. The gel shift of 
the RNA probe illustrates the binding of FUS protein to the RNA probe. The work in (D) 
was done by Chunyan Niu in Dr. Weimin Gong’s lab in the Chinese Academy of Science 
in Beijing, China. 
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Figure 4.8 RNA binding was also required for FUS cytoplasmic inclusion formation 
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Figure 4.9 The proposed model of FUS distribution and architecture in different 
cellular compartments.  
The left side shows that chromatin-associated RNAs initiate FUS oligomerization 
through the QGSY-rich region in the nucleus. Nuclear soluble and cytoplasmic FUS 
normally exists as monomers under physiological conditions. The right side shows that 
ALS mutations cause cytoplasmic retention of FUS. However, mutant FUS in the nucleus 
was still able to oligomerize similarly to wild-type FUS. The cytoplasm-retained FUS 
forms relatively disordered inclusions that require binding cytoplasmic RNAs. 
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Figure 4.9 The proposed model of FUS distribution and architecture in different 
cellular compartments 
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Chapter 5: Arginine Methylation Regulates FUS Chromatin Binding and 
Transcription Regulation Ability 
Introduction 
FUS plays a fundamental role in regulating gene transcription since it can directly 
interact with RNA polymerase II [63, 100, 128] and depletion of it changed the mRNA 
level of hundreds of genes in mouse brain and cultured cells [63, 64]. However, the exact 
mechanism through which FUS regulate gene transcription is not clear. In our previous 
study [138], we found that transcription regulation mediated by FUS requires its 
oligomerization and chromatin binding through the QGSY-rich region in the N-terminus 
of FUS. We also found mutations, which cause familial ALS, significantly reduce FUS 
chromatin binding. As a consequence, those ALS mutations may also impair FUS-
mediated transcription regulation. Indeed, the expression of MnSOD gene, a FUS 
regulated gene encoding the primary antioxidant enzyme in the mitochondria, is 
significantly reduced in ALS patient fibroblasts as compared to in normal controls [110].  
Post-translational modifications of proteins play important roles in regulating 
their distribution and function. Phosphorylation [149, 150] and arginine methylation 
[151] are the two post-translational modifications on FUS that have been reported. 
Phosphorylation of FUS plays an important role for its participation in DNA damage 
repair [152, 153]. Methylation on the arginine residues in FUS has been reported to 
regulate its nucleus/cytoplasm localization [107, 108, 140, 141]. Arginine methylation is 
catalyzed by protein arginine methyltransferases (PRMTs) which transfer methyl groups 
from S-adenosyl methionine to the guanidino nitrogen of arginine residues [106]. The 
primary enzyme for FUS arginine methylation is PRMT1 [107, 108]. 
FUS has three arginine-glycine-glycine (RGG) repeat regions interspersed 
between different functional motifs. Two of them are critical for FUS RNA binding 
ability [Chapter 2]. The RGG repeats are typical substrates of PRMTs [106]. It is 
important to know whether FUS arginine methylation occurs in the RGG repeats, since 
any of the modifications in these regions may affect FUS RNA binding ability.  
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In this study, we found that FUS arginine methylation can regulate its chromatin 
binding and transcription regulation ability. We first confirmed that FUS arginine 
methylation mainly takes place in the RGG-repeat regions. We then discovered 
methylation inhibition increased the level of chromatin-bound FUS. By knocking-down 
and over-expression of PRMT1, we found that arginine methylation can regulate FUS 
chromatin binding. With cells expressing mutant FUS, we found that methylation 
inhibition restored mutant FUS binding to active chromatin. With reporter gene plasmid 
containing MnSOD gene promotor, we found that arginine methylation regulated FUS 
transcription activation ability. Together, our results suggest arginine methylation can be 
used as handle to reverse ALS mutations-caused FUS physiological function loss.   
Results 
FUS is arginine-methylated in the RGG repeat regions 
To probe arginine methylation regions in FUS, we made a series of constructs 
expressing FUS truncation mutants (Figure 5.1A left) and transfected them in HEK cells. 
GST-tagged FUS truncation mutants were pulled-down by glutathione beads and 
subjected to SDS/PAGE and Western blot with methylarginine antibody. As shown in 
Figure 5.1A right, full length FUS arginine methylation was confirmed as no 
methylarginine detected in the GST tag itself. By comparing methylarginine level of FUS 
1-164 to FUS 165-284 and FUS 1-370 to FUS 1-494, we detected that the glycine-rich 
region (165-284) and zinc finger domain (371-494) are two main arginine methylation 
regions in FUS (Figure 5.1A right).  
Glycine-rich region contains the first RGG repeat region (RGG1); zinc finger 
domain contains the other two RGG repeat regions (RGG2 and RGG3) (Figure 5.1B left). 
We further truncated FUS in zinc finger domain (Figure 5.1B left) and did the same GST 
pull-down and Western blot. As shown in Figure 5.1B right, while the deletion of either 
RGG2 (370-409) or RGG3 (472-494) resulted in methylarginine level decrease, the 
deletion of zinc finger motif did not change methylarginine level. The result indicates 
zinc finger domain arginine methylation mainly takes place in RGG2 and RGG3.   
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Inhibition of arginine methylation enhanced FUS chromatin binding 
Adenosine dialdehyde (AdOx) is an inhibitor of S-adenosylhomocysteine 
hydrolase [154], an enzyme critical for the regeneration of the methyl group donor--S-
adenosyl methionine. We found AdOx treatment significantly increased FUS protein 
level isolated together with chromatin (Figure 5.2A). HEK cells were grown in the 
medium containing 20 μM AdOx before we isolated the chromatin-bound proteins using 
the protocol described previously. A corresponding decrease of FUS protein levels in the 
soluble fraction was also detected (Figure 5.2A). The result indicates methylation 
inhibition enhanced FUS chromatin binding.  
To see how FUS arginine methylation was affected by AdOx, we 
immunoprecipitated FUS out of soluble fractions in Figure 5.2A and did Western blot 
with methylarginine antibody. As shown in Figure 5.2B, at high AdOx concentrations 
FUS arginine methylation was not detectable, indicating high concentration AdOx 
inhibited FUS arginine methylation.  
PRMT1 regulates FUS arginine methylation and chromatin binding 
The results of methylation inhibition experiment indicate there is a correlation 
between FUS chromatin binding and arginine methylation. To test whether FUS arginine 
methylation is a causal factor of its chromatin binding, we knocked-down PRMT1, the 
primary enzyme for FUS arginine methylation, with siRNA in HEK cells and did FUS 
immunoprecipitation and chromatin-bound protein isolation. As shown in Figure 5.3A, 
PRMT1 knock-down reduced FUS arginine methylation level significantly. As a 
consequence, chromatin-bound FUS from PRMT1 knock-down samples increased 
significantly comparing to chromatin-bound FUS from control siRNA samples (Figure 
5.3B). On the opposite direction, we over-expressed PRMT1 in HEK cells and did FUS 
immunoprecipitation and chromatin-bound protein isolation. Increasing amounts of 
pCMV2B-PRMT1 plasmids were transfected into HEK cells. As shown in Figure 5.4A, 
over-expression of PRMT1 increased FUS arginine methylation level in a dose-
dependent manner. With higher arginine methylation level, less FUS was detected in 
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chromatin-bound fraction (Figure 5.4B). Together, the results suggest that FUS 
chromatin binding is likely regulated by its own arginine methylation. 
Suppression of arginine methylation restored mutant FUS binding to active 
chromatin domains. 
Since ALS mutations significantly reduce FUS chromatin binding and loss of 
FUS on chromatin may cause extensive transcription dysregulation [63, 64, 138], we 
wanted to test whether suppression of arginine methylation can reverse mutation-caused 
FUS loss on chromatin. For this purpose, we treated HEK cells expressing mutant FUS 
with AdOx and separated chromatin-bound and non-chromatin-bound proteins with 
chromatin salt elution method (Figure 5.5A). As described in Chapter 1, chromatin salt 
elution can separate active chromatin domains from inactive chromatin domains. The 
reason we fractionated chromatin was to make sure that the restored chromatin-bound 
mutant FUS was in the transcriptionally active chromatin domains. As shown in Figure 
5.5, R521G mutation resulted in a decrease of FUS protein level in the E1 fraction, which 
mainly contains active chromatin domains as indicated by histone immunoblots, 
comparing with wild-type FUS fractionation (Figure 3.3). With AdOx treatment, which 
suppresses FUS arginine methylation, a substantial increase of the amount of FUS in the 
E1 fraction was detected (Figure 5.5C). We also showed the DNA contents in each 
fraction in Figure 5.5B agarose gel image. The result suggests suppression of arginine 
methylation can reverse the effect of ALS mutation on FUS chromatin binding.   
Arginine methylation regulates FUS-mediated transcription activation 
We next asked whether arginine methylation can regulate the gene transcriptions 
mediated by FUS. For this purpose, we used a dual-luciferase assay as described in 
Chapter 3 with a firefly luciferase gene driven by the MnSOD promoter (Figure 5.6A). 
We cotransfected the luciferase plasmids with either PRMT1 siRNA or plasmid into 
HEK cells and did the luciferase assay as described in Chapter 2. We found PRMT1 
knock-down significantly increased MnSOD promoter activity, whereas PRMT1 over-
expression significantly decreased MnSOD promoter activity (Figure 5.6B). The result is 
strongly correlated with PRMT1-regulated FUS chromatin binding ability (Figure 5.3 and 
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5.4). Since the MnSOD promoter is bound and activated by FUS [110], the result 
suggests FUS arginine methylation can regulate its transcription activation ability through 
adjusting its chromatin binding. We also tested how FUS transcription regulation ability 
was affected by a series of compounds that are inhibitors of methionine S-
adenosyltransferase 2A and expected to reduce S-adenosyl methionine levels in cells 
[155] (Figure 5.6C). The VMS compounds were generously provided by Dr. David Watt 
in our department. 
Discussion 
In this study, we found arginine methylation can regulate FUS chromatin binding 
and transcription regulation ability. This funding suggests that arginine methylation can 
be used as a handle to reverse ALS-mutation-caused FUS chromatin dissociation and 
transcription activation deficiency. Indeed, we showed evidence that suppression of 
arginine methylation can restore mutant FUS binding to the active chromatin domains.  
Both AdOx and PRMT1 knock-down involves more targets than just FUS. 
Cautions should be given when interpreting the relation between FUS chromatin binding 
and its own arginine methylation. This situation can be worse in the case of transcription 
regulation since a lot of transcription factors are also the substrate of PRMT1 [106]. With 
our own data we cannot exclude the possibility that other transcription factors also 
participated in PRMT1-regulated MnSOD promotor activity. However, our primary goal 
is to reverse FUS chromatin-dissociation caused by ALS mutations. Although other 
proteins may be also involved or even play primary roles in this process, we can also 
achieve our goal, but with a caution of the side effects. From this comes our motivation to 
test arginine methylation modulators with our reporter gene assay. Our ultimate objective 
is to identify arginine methylation modulators which can reverse ALS mutation effects on 
FUS while have no or very little toxic effects on cells.  
Chromatin binding may also be required for FUS DNA damage repair [61]. In the 
paper published by Mastrocola, A.S., et al., the authors showed that FUS was recruited to 
DNA damage sites shortly after laser-induced micro-irradiation. But if N-terminal 
disordered region of FUS was deleted, the recruitment of FUS to DNA damage sites was 
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almost abolished. Since FUS N-terminus is responsible for its chromatin binding, it is 
conceivable that chromatin binding may also be important for the response of FUS to 
DNA damages. Therefore the restoration of mutant FUS chromatin binding driven by 
arginine methylation suppression may show beneficial effects in a broader range than just 
transcription regulation.  
We do not know the exact mechanism by which arginine methylation regulates 
FUS chromatin binding. But we detected that arginine methylation mainly takes place in 
RGG repeat regions (Figure 5.1). Two of them, RGG2 and RGG3, are very important for 
FUS RNA binding ability (Figure 4.8). The mechanism is considered to be that the 
charge-charge interaction--the positive charges of arginine guanidinium groups in the 
RGG repeats and the negative charges of phosphates in RNA--enhances the binding 
affinity of FUS to RNA. Methylation on guanidino nitrogen may alter the charge 
distribution in guanidinium group or disturb the charge-charge interaction by steric 
effects. Therefore arginine methylation may reduce the binding affinity of FUS to RNA. 
With regard to the role of RNA in FUS oligomerization and chromatin binding, it is very 
likely that arginine methylation regulates FUS chromatin binding through alteration of its 
binding affinity to RNAs. 
Arginine methylation suppression has shown beneficial effects in model 
organisms with transgenic expression of FUS or FUS mutants [108, 139, 141]. The 
mechanism is probably the relocation of mutant FUS from the cytoplasm to the nucleus, 
driven by arginine methylation suppression. In ALS patients, both cytoplasmic FUS 
accumulation and nuclear FUS loss happen. Our finding that arginine methylation 
suppression can increase FUS chromatin binding together with its reported toxicity-
reducing effect with mutant FUS suggest suppression of arginine methylation may serve 
as an effective approach to save motor neurons from FUS ALS mutations.  
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Figure 5.1 FUS arginine methylation occurs in the RGG-repeat regions. 
(A) FUS arginine methylation was mainly detected in the glycine-rich region and zinc 
finger domain. Diagram shows the GST-tagged FUS and FUS truncation mutants and the 
RGG-repeat regions. Western blot of GST pull-down products was performed with 
methylarginine antibody and GST antibody. (B) Zinc finger domain arginine methylation 
was mainly detected in RGG2 and RGG3. Diagram shows FUS zinc finger domain 
truncation mutants and RGGs. Western blot was done as described in A.  
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Figure 5.1 FUS arginine methylation occurs in the RGG-repeat regions 
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Figure 5.2 Methylation inhibition enhanced FUS chromatin binding. 
(A) The chromatin-bound FUS was increased by methylation inhibition. Cells were 
grown in media containing methylation inhibitor AdOx at indicated concentrations. 
Chromatin-bound proteins were isolated as in Figure 3.1A and Western blot was 
performed with FUS and Histone H3 antibodies. (B) FUS arginine methylation was 
inhibited by AdOx. FUS was immunoprecipitated from soluble fractions in A and and 
Western blot was performed with methylarginine and FUS antibodies. 
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Figure 5.2 Methylation inhibition enhanced FUS chromatin binding 
 
 
   
100 
 
Figure 5.3 Knock-down of PRMT1 suppressed FUS arginine methylation and 
enhanced FUS chromatin binding. 
(A) PRMT1 knock-down decreased FUS methylarginine level. Western blot was 
performed with FUS immunoprecipitation product and methylarginine and FUS 
antibodies. The ratio of methylarginine and FUS was quantified and the results from three 
independent experiments are presented. (B) PRMT1 knock-down increased FUS protein 
level in the chromatin-bound fraction. Western blot was performed with FUS, Histone 
H3, and PRMT1 antibodies. The ratio of chromatin-bound and soluble FUS was 
quantified and the results from three independent experiments are presented. 
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Figure 5.3 Knock-down of PRMT1 suppressed FUS arginine methylation and 
enhanced FUS chromatin binding 
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Figure 5.4 PRMT1 over-expression increased FUS arginine methylation and 
weakened FUS chromatin binding. 
(A) PRMT1 over-expression increased FUS arginine methylation. Western blot was 
performed with methylarginine and FUS antibodies. The ratio of methylarginine and FUS 
with 1μg FLAG or FLAG-PRMT1 plasmid transfected was quantified and the results 
from three independent experiments are presented. (B) PRMT1 over-expression reduced 
FUS protein level in the chromatin-bound fraction. Western blot was performed with 
FUS, Histone H3, and FLAG antibodies. The ratio of chromatin-bound and soluble FUS 
with 1μg FLAG or FLAG-PRMT1 plasmid transfected was quantified and the results 
from three independent experiments are presented. 
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Figure 5.4 PRMT1 over-expression increased FUS arginine methylation and 
weakened FUS chromatin binding 
 
 
 
   
104 
 
Figure 5.5 Methylation suppression restored mutant FUS binding to active 
chromatin domains. 
(A) Flowchart of chromatin fractionation as in Figure 3.3A. (B) DNA fragments from 
each fraction. DNA fragments were purified with proteinase K treatment and PCR 
product purification kit and separated by agarose gel electrophoresis. (C) AdOx treatment 
restored the level of EGFP-FUS R521G in the E1 fraction. Chromatin from the cells 
expressing wild-type or mutant FUS with or without AdOx treatment was fractionated.  
Western blot was performed with indicated antibodies. 
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Figure 5.5 Methylation suppression restored mutant FUS binding to active 
chromatin domains 
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Figure 5.6 Arginine methylation regulates MnSOD promotor activity. 
(A) Diagram of the dual-luciferase assay plasmids. Firefly luciferase gene is driven by 
MnSOD promoter and renilla luciferase gene is driven by HSV TK promoter. (B) 
MnSOD promoter activity was regulated by PRMT1. HEK cells were cotransfected with 
the luciferase plasmids and PRMT1 siRNA or FLAG-PRMT1 plasmid two days before 
lysis and dual luciferase assay. The results from three independent experiments are 
presented. *: p<0.05. (C) MnSOD promoter activity was affected by methionine S-
adenosyltransferase 2A inhibitors. The VMS compounds were generously provided by 
Dr. David Watt in our department. HEK cells transfected with the luciferase plasmids 
were treated with 20 μM of each compound two days before lysis and dual luciferase 
assay.  
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Figure 5.6 Arginine methylation regulates MnSOD promotor activity. 
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Chapter 6: Summary and Future Directions 
In this dissertation research, we revealed how wild-type FUS is organized in the 
nucleus for its multiple functions and discovered that disassociation of FUS from 
chromatin is a common consequence of ALS mutations. Considering the necessity of 
chromatin binding in FUS-mediated transcription regulation, the finding suggests that 
disturbed transcription regulation can be a consequence of the ALS mutation-caused FUS 
loss-of-function in the nucleus. Moreover we identified a posttranslational modification, 
namely arginine methylation, can reverse the reduced association between mutant FUS 
and chromatin. We further identified RNAs are a critical factor determining FUS 
organization in the nucleus and the cytoplasm. In the nucleus, RNA triggers FUS 
oligomerization, providing a potential mechanism of the coexistence of two functionally 
distinctive pools of FUS. In the cytoplasm, mutant FUS inclusion formation is also RNA-
dependent, supporting the notion that the pathogenic mechanism of mutant FUS is 
different from the widely-accepted pathogenic mechanism of non-RNA-binding protein 
misfolding/aggregation.  
Below, I will discuss the potential implications of the findings in this dissertation 
and propose future directions which may solidify the conclusions and further extend our 
understanding of FUS physiology and pathology.  
FUS oligomerizes in the nucleus to regulate gene transcription 
FUS has multiple functions in the nucleus but it is unknown how nuclear FUS is 
deployed for its multiple roles. We found that a portion of nuclear FUS is bound to active 
chromatin and the remainder of FUS is free in the nucleoplasm. Chromatin-bound FUS is 
designated for gene transcription regulation whereas free nuclear FUS can regulate 
mRNA alternative splicing. This finding suggests that cells ensure the fulfilment of FUS’ 
multiple roles by allocating FUS molecules into different pools, instead of coupling 
different cellular processes that FUS participates in.  
We identified oligomerization as a way through which cells allocate FUS 
molecules for chromatin binding and nucleoplasm diffusing. Only oligomerized FUS can 
bind chromatin. Interestingly, the oligomerization domain of FUS is part of a prion-like 
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domain which was previously considered bad because of its aggregation-prone property. 
Regarding the fact that RNA binding proteins have the highest odds to possess a prion-
like domain [96], our finding indicates a prion-like domain in RNA binding proteins is 
physiologically important, rather than a mere evolutionary accident.  
However, with this notion we still do not know how cells initiate FUS 
oligomerization to execute its transcription regulation function. Besides the QGSY-rich 
region, which is an intrinsic determinant of FUS oligomerization, RNA was identified as 
an extrinsic determinant of FUS oligomerization. In Chapter 3, we showed RNA is 
required for FUS oligomerization. In Chapter 4, we confirmed the RNA dependency of 
FUS oligomerization and discovered chromatin-associated RNAs are the trigger of FUS 
oligomerization. The identification of the RNA-triggered oligomerization explains the 
coexistence of chromatin-bound oligomerized FUS and free FUS in the nucleus. We 
therefore speculate that cells may determine the proportion of chromatin-bound FUS and 
free FUS by transcribing certain RNAs when it is necessary.  
We found the significant loss of chromatin-bound FUS as a consequence of ALS 
mutations, suggesting ALS mutations can subsequently cause interference in FUS 
mediated transcription regulation. This notion is supported by the fact that MnSOD gene 
expression is significantly decreased in fibroblasts from ALS patients compared to in 
control fibroblasts [110]. FUS plays a fundamental role in gene transcription regulation. 
In liposarcoma-causing oncogenic fusion protein, where FUS was first identified and 
named, the transcription activation capability is carried by the FUS part [156, 157]. FUS 
has been reported as a direct interaction partner of RNA polymerase II [63, 100, 128, 
129]. In FUS knock-out mouse brain, the mRNA level of hundreds of genes was changed 
to a significant level [64]. In FUS knock-down HEK cells, the transcription regulation of 
hundreds of genes were disturbed [63]. An interesting observation in these two genome-
wide studies was that the average change of the mRNA levels of FUS-regulated genes is 
about two folds—a level considered low compared to the genes regulated by other 
transcription factors. We detected about the same level of mRNA change in FUS over-
expressing cells (Chapter 3). We speculate that FUS plays a fundamental role in fine 
tuning gene transcription in a large scale rather than certain specific genes. Considering 
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the late onset of ALS, it is conceivable that the accrued broad-range transcription 
dysregulation can eventually kill motor neurons. 
RNA determines FUS organization in different cellular compartments   
Nuclear FUS appears granular under confocal microscope, so does the nucleus-
localized mutant FUS. The primary function of FUS nuclear granules is transcription 
regulation. The structural basis of FUS nuclear granules is the QGSY-rich region 
mediated oligomerization. In Chapter 3 and Chapter 4, we showed FUS oligomerization 
was triggered by chromatin-associated RNAs. An immediate question following this 
discovery is what the identities of the trigger RNAs are.  
Mutant FUS forms inclusions in motor neuron cytoplasm. This histopathological 
feature can be recapitulated in cultured cells (Chapter 4). In Chapter 4, we showed 
cytoplasmic inclusion formation also requires FUS RNA binding ability. Indeed RNA 
and RNA binding proteins have been frequently reported in FUS inclusions [55, 56, 87, 
104, 158]. The finding that RNA plays a critical role in mutant FUS inclusion formation 
raises two interesting questions. First, what is the exact role of RNA in FUS inclusions? 
Or whether cytoplasmic RNAs trigger FUS inclusion formation? The answer can help us 
better understand why FUS inclusions are so structurally different from inclusions 
formed by other misfolded proteins. The future studies will also examine the effect of 
mutant FUS on normal stress granule formation. Second, what are the identities of FUS 
inclusion-trapped RNAs?  Not like stress granules, which are temporary structures, FUS 
inclusions are persistent. When the stress ebbs away, stress granule RNAs, which are 
typically messenger RNAs, are released and subjected to translation [57, 159]. However, 
FUS inclusion-trapped RNAs are persistently sequestered, thus functional loss will likely 
occur in cellular processes involving the participation of these RNAs or their protein 
products. Therefore, the identification of FUS inclusion-trapped RNAs can help us 
discover potential new pathways that might me impaired by mutant FUS. 
To identify these FUS-bound RNAs, we plan to do FUS immunoprecipitation and 
RNA sequencing. The strategy is first to crosslink FUS and targeting RNAs with 
ultraviolet light, and then to isolate chromatin from wild-type FUS expressing cells or 
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cytoplasm from mutant FUS expressing cells. Chromatin will be fragmented and 
dissolved by sonication. The targeting RNAs will be enriched by FUS 
immunoprecipitation and purified for sequencing. We will compare our sequencing 
results with the published FUS-bound RNA database to identify specific RNA species. 
There are attractive applications if we know the identities and sequences of FUS 
organization-determining RNAs. First, for nuclear regulatory RNAs, we will search (if 
they are known RNA species) or investigate (if they are unknown RNA species) how 
their transcription is regulated and target their transcription-regulating factors to nudge 
FUS intranuclear distribution to a favorable way. Second, after we know the sequences of 
nuclear regulatory RNAs, we can design RNA probes to alter mutant FUS distribution or 
inclusion formation in the cytoplasm, since nuclear RNAs can trigger mutant FUS 
oligomerization (Chapter 4). Third, the identities of FUS inclusion-trapped RNAs can 
help us identify new potential pathways that are disturbed by mutant FUS.  
Arginine methylation regulates FUS chromatin binding 
We found that a posttranslational modification—methylation on arginine—can 
regulate FUS chromatin binding. Arginine methylation was studied less comprehensive 
than phosphorylation due to the late identification of arginine methyltransferases [106]. 
The main cellular activities regulated by arginine methylation are gene expression, DNA 
damage repair, and signal transduction [106]. Therefore the finding that arginine 
methylation can regulate FUS chromatin binding supports the notion that chromatin 
binding plays an important role in FUS-mediated gene transcription regulation and 
genome stability maintenance. 
In Chapter 5, we narrowed down arginine methylation areas in FUS mainly to 
three short sequences: the glycine-rich region and two arginine-glycine-glycine rich 
regions (RGG2 and RGG3) flanking zinc finger motif. In Chapter 4, we demonstrated 
RGG2 and RGG3 were critical for FUS RNA binding in vitro. We also discussed the 
potential mechanism of arginine methylation regulated FUS chromatin binding in 
Chapter 5. Methylation on arginine residues in RGG2 and RGG3 can alter their affinity 
to RNA, which plays critical role in FUS oligomerization and chromatin binding. This is 
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our speculation and we plan to test it experimentally. The strategy is to use the same in 
vitro RNA binding assay, but with different FUS fragments expressing cells. We used E. 
coli in the experiment in Chapter 4; we plan to use mammalian cells to express FUS 
fragments in the proposed experiment. The advantage of mammalian cells is that we can 
control FUS fragments arginine methylation level by adding methylation inhibitors or 
over-expressing PRMT1. The potential implication of the result of the proposed 
experiment can be very important because RNA binding ability is critical not only in FUS 
chromatin binding but also in many other FUS-participated cellular activities. 
We showed evidence that both methylation inhibitor and PRMT1 knock-down 
can suppress FUS arginine methylation and increase FUS chromatin binding. PRMT1 
enzymatic activity can be pharmacologically inhibited [160]. These facts suggest small 
compounds modulating either methylation or PRMT1 activity may be applied to restore 
chromatin binding of mutant FUS. We hope that by screening methylation modulators we 
can find candidates with beneficial effects of a low arginine methylation level while 
avoiding cell toxicity. We can use a FUS chromatin binding assay to do the screening 
either in HEK cells or in primary neurons. 
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